Non-syndromic X-linked intellectual disability (NS-XLID; historically MRX, and designated IDX in the contemporary family series) is the class of X-linked intellectual disability in which impaired intellectual functioning and adaptive behaviour are the only consistent shared feature. Critically, "non-syndromic" does not mean that every affected individual has isolated intellectual disability - variable speech delay, hypotonia, seizures, autistic traits, or minor dysmorphism may coexist - it means that no additional feature is reproducible across the families or disorders carrying the label. It is the third member of the non-syndromic intellectual-disability trio alongside the autosomal dominant and autosomal recessive classes, and is distinguished from both by its inheritance architecture: hemizygous males express a single mutant X allele in every cell, while heterozygous females express it only in the cells where the mutant X remains active, and are typically unaffected or mildly affected. That asymmetry, together with the reproducible male excess among people with intellectual disability (approximately 1.3-1.4 to 1), made X-linked defects the classical explanation for the sex-ratio imbalance and concentrated three decades of gene discovery on a single chromosome - one that carries about 5% of the human genome but about 15% of known intellectual-disability genes. Two structural facts define the class. First, it is extremely genetically heterogeneous while being clinically homogeneous: families were numbered by linkage interval (MRX1, MRX2, ...) rather than by phenotype, because there was no phenotype to distinguish them, and each individual gene accounts for only a small percentage of cases. Of 105 non-syndromal families assigned IDX numbers, 67 have a cloned gene, 33 are mapped without an identified gene, and 5 remain unpublished. Second, the boundary with the syndromic (MRXS) class is unstable and, on the authoritative view, blurred and sometimes arbitrary: 28 of the IDX genes are also associated with XLID syndromes, genes first reported as causing pure MRX acquire recognisable features once larger series are phenotyped, and allelic series place non-syndromic and severely syndromic phenotypes at opposite ends of one gene's mutation spectrum. ARX is the canonical example, spanning nonsyndromal XLID at one end and lissencephaly with abnormal genitalia at the other. Mechanistically the causal genes do not converge on a single pathway, but they fall repeatedly into a limited set of themes: Rho GTPase signalling to the actin cytoskeleton (PAK3), Rab-dependent synaptic vesicle recycling (GDI1), proposed roles in excitatory synapse formation and neurite outgrowth (IL1RAPL1, TSPAN7), tRNA anticodon-loop modification and translational fidelity (FTSJ1), lipid metabolism (ACSL4), Golgi pH regulation and glycosylation (SLC9A7), and telencephalic transcriptional control (ARX). The unifying pathology is a functional lesion of synaptic plasticity in an anatomically normal brain - a mis-tuned rather than a mis-built or damaged circuit - which is why neuroimaging is characteristically unremarkable. The class is conventionally described as static rather than progressive, though no source cited in this entry quantifies its temporal course. A critical caveat governs curation of this class. Because genes were nominated from small families before large population control sets existed, a systematic reassessment against 10,563 control X chromosomes challenged 25 of the 106 genes then accepted; as of the 2017 update, 17 of those 25 remain unresolved. Gene lists for this class published before roughly 2013 should not be treated as settled.
Ask a research question about Non-Syndromic X-Linked Intellectual Disability. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Non-Syndromic X-Linked Intellectual Disability:
name: Non-Syndromic X-Linked Intellectual Disability
creation_date: "2026-08-12T00:00:00Z"
description: >-
Non-syndromic X-linked intellectual disability (NS-XLID; historically MRX,
and designated IDX in the contemporary family series) is the class of
X-linked intellectual disability in which impaired intellectual functioning
and adaptive behaviour are the only consistent shared feature. Critically,
"non-syndromic" does not mean that every affected individual has isolated
intellectual disability - variable speech delay, hypotonia, seizures,
autistic traits, or minor dysmorphism may coexist - it means that no
additional feature is reproducible across the families or disorders carrying
the label. It is the third member of the non-syndromic
intellectual-disability trio alongside the autosomal dominant and autosomal
recessive classes, and is distinguished from both by its inheritance
architecture: hemizygous males express a single mutant X allele in every
cell, while heterozygous females express it only in the cells where the
mutant X remains active, and are typically unaffected or mildly affected.
That asymmetry, together with the reproducible male excess among people with
intellectual disability (approximately 1.3-1.4 to 1), made X-linked defects
the classical explanation for the sex-ratio imbalance and concentrated three
decades of gene discovery on a single chromosome - one that carries about 5%
of the human genome but about 15% of known intellectual-disability genes.
Two structural facts define the class. First, it is extremely genetically
heterogeneous while being clinically homogeneous: families were numbered by
linkage interval (MRX1, MRX2, ...) rather than by phenotype, because there
was no phenotype to distinguish them, and each individual gene accounts for
only a small percentage of cases. Of 105 non-syndromal families assigned IDX
numbers, 67 have a cloned gene, 33 are mapped without an identified gene,
and 5 remain unpublished. Second, the boundary with the syndromic (MRXS)
class is unstable and, on the authoritative view, blurred and sometimes
arbitrary: 28 of the IDX genes are also associated with XLID syndromes,
genes first reported as causing pure MRX acquire recognisable features once
larger series are phenotyped, and allelic series place non-syndromic and
severely syndromic phenotypes at opposite ends of one gene's mutation
spectrum. ARX is the canonical example, spanning nonsyndromal XLID at one
end and lissencephaly with abnormal genitalia at the other.
Mechanistically the causal genes do not converge on a single pathway, but
they fall repeatedly into a limited set of themes: Rho GTPase signalling to
the actin cytoskeleton (PAK3), Rab-dependent synaptic vesicle recycling
(GDI1), proposed roles in excitatory synapse formation and neurite
outgrowth (IL1RAPL1, TSPAN7), tRNA anticodon-loop modification and translational fidelity
(FTSJ1), lipid metabolism (ACSL4), Golgi pH regulation and glycosylation
(SLC9A7), and telencephalic transcriptional control (ARX). The unifying
pathology is a functional lesion of synaptic plasticity in an anatomically
normal brain - a mis-tuned rather than a mis-built or damaged circuit -
which is why neuroimaging is characteristically unremarkable. The class is
conventionally described as static rather than progressive, though no source
cited in this entry quantifies its temporal course.
A critical caveat governs curation of this class. Because genes were
nominated from small families before large population control sets existed,
a systematic reassessment against 10,563 control X chromosomes challenged 25
of the 106 genes then accepted; as of the 2017 update, 17 of those 25 remain
unresolved. Gene lists for this class published before roughly 2013 should
not be treated as settled.
category: Genetic
disease_term:
preferred_term: non-syndromic X-linked intellectual disability
term:
id: MONDO:0019181
label: non-syndromic X-linked intellectual disability
parents:
- Non-Syndromic Intellectual Disability
- X-Linked Intellectual Disability
synonyms:
- X-linked non-specific intellectual disability
- X-linked non-syndromic intellectual disability
- intellectual disability, X-linked, nonsyndromic
- non-specific X-linked intellectual disability
- isolated X-linked intellectual disability
- nonsyndromic X-linked mental retardation
- NS-XLID
- MRX
- IDX
references:
- reference: PMID:31898314
title: "Non-syndromic X linked intellectual disability: Current knowledge in light of the recent advances in molecular and functional studies."
- reference: PMID:29696803
title: "X-linked intellectual disability update 2017."
- reference: PMID:22482801
title: "Fragile X and X-linked intellectual disability: four decades of discovery."
- reference: PMID:23871722
title: "XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing."
- reference: PMID:19377476
title: "A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation."
- reference: PMID:15630421
title: "X-linked mental retardation."
- reference: PMID:31906484
title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
- reference: PMID:38424476
title: "Overcoming genetic and cellular complexity to study the pathophysiology of X-linked intellectual disabilities."
inheritance:
- name: X-linked
description: >-
Causal variants lie on the X chromosome. Hemizygous males carry a single
copy of the mutant allele with no second copy to compensate and are fully
affected; heterozygous females are usually unaffected or only mildly
affected, because random X-chromosome inactivation makes them mosaic for
expression of the mutant allele. In several subtypes carrier females show
completely skewed X-inactivation that silences the mutant X and confers
additional protection. There is no male-to-male transmission. Large
multiplex pedigrees showing this segregation pattern were the substrate
for the linkage studies that defined the numbered MRX/IDX series, and the
relative ease of ascertaining such families is why X-linked intellectual
disability was delineated far ahead of its autosomal counterparts.
inheritance_term:
preferred_term: X-linked inheritance
term:
id: HP:0001417
label: X-linked inheritance
expressivity: VARIABLE
evidence:
- reference: PMID:38424476
reference_title: "Overcoming genetic and cellular complexity to study the pathophysiology of X-linked intellectual disabilities."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This is because most genes on the X chromosome are subject to random X
chromosome inactivation (XCI) during early embryonic development, which
results in a mosaic pattern of gene expression for a given X-linked
mutant allele.
explanation: >-
Establishes the mosaic-expression mechanism that makes heterozygous
females variably and usually mildly affected relative to hemizygous
males.
- reference: PMID:11889465
reference_title: "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All carrier females with either point mutations or genomic deletions in
FACL4 showed a completely skewed X-inactivation, suggesting that the
gene influences survival advantage.
explanation: >-
Documents the completely skewed X-inactivation that spares carrier
females, using the ACSL4/FACL4 subtype as the worked example.
- reference: PMID:22482801
reference_title: "Fragile X and X-linked intellectual disability: four decades of discovery."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Progress in delineating XLID has far outpaced the efforts to understand
the genetic basis for autosomal intellectual disability. In large
measure, this has been because of the relative ease of identifying
families with XLID and finding the responsible mutations
explanation: >-
Explains why this class was characterised ahead of its autosomal
counterparts: X-linked segregation makes multiplex families
straightforward to ascertain.
prevalence:
- population: Males, worldwide
measure_type: POINT_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_per_100000: 166.7
notes: >-
Estimate for X-linked intellectual disability as a whole (syndromic plus
non-syndromic), given in the source as approximately 1 in 600 males. The
non-syndromic class is a subset of this figure; no robust population
prevalence exists for the non-syndromic class alone, because it aggregates
many individually rare gene-defined disorders.
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
X-linked forms of mental retardation (MR) affect approximately 1 in 600
males and are likely to be highly heterogeneous.
explanation: >-
Provides the population rate for X-linked intellectual disability as a
whole. Marked PARTIAL because the figure covers syndromic and
non-syndromic forms together, not the non-syndromic class this entry
describes.
- population: Males with intellectual disability
measure_type: UNKNOWN
prevalence_class: COMMON
notes: >-
X-linked intellectual disability (syndromic and non-syndromic combined)
accounts for 5-10% of intellectual disability in males, and is the
classical explanation for the male excess observed among people with
intellectual disability. `measure_type: UNKNOWN` is deliberate: this is a
case fraction within an already-affected population rather than a
population rate, and no source defines a time interval, so none of the
prevalence/incidence measure types applies.
evidence:
- reference: PMID:22482801
reference_title: "Fragile X and X-linked intellectual disability: four decades of discovery."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
X-Linked intellectual disability (XLID) accounts for 5%-10% of
intellectual disability in males.
explanation: >-
Quantifies the fraction of male intellectual disability attributable to
X-linked causes.
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
X-linked intellectual disability (XLID) is known to contribute up to 10%
of intellectual disability (ID) in males and could explain the increased
ratio of affected males observed in patients with ID.
explanation: >-
Independent confirmation of the 10% upper bound and explicit statement
that it explains the male excess.
has_subtypes:
- name: MRX21
display_name: Intellectual disability, X-linked 21 (IL1RAPL1)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 21
term:
id: MONDO:0010256
label: intellectual disability, X-linked 21
genes:
- preferred_term: IL1RAPL1
term:
id: hgnc:5996
label: IL1RAPL1
description: >-
Deletions and loss-of-function point variants in IL1RAPL1 at Xp22.1-21.3,
encoding an interleukin-1 receptor accessory protein family member highly
expressed in postnatal hippocampus. The founding report explicitly describes
patients with cognitive impairment only, one of the clearest original
descriptions in the class - though see the caveat below on later
families. IL1RAPL1 is understood to act in excitatory synapse
formation, though the cited primary report establishes only its
hippocampal expression and infers a role in memory and learning. Later series identified
behavioural problems and mild dysmorphism in some families, illustrating
the instability of the non-syndromic label.
evidence:
- reference: PMID:10471494
reference_title: "A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Non-overlapping deletions and a nonsense mutation in this gene were
identified in patients with cognitive impairment only.
explanation: >-
Establishes the IL1RAPL1 subtype and, critically, its purely
non-syndromic presentation - cognitive impairment as the sole feature.
- reference: PMID:10471494
reference_title: "A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Its high level of expression in post-natal brain structures involved in
the hippocampal memory system suggests a specialized role for this new
gene in the physiological processes underlying memory and learning
abilities.
explanation: >-
Links the subtype to hippocampal learning circuitry, the anatomical
substrate shared across the class. Tagged MODEL_ORGANISM: the expression
analysis is animal tissue work (the paper's MeSH terms include Mice),
and the role in memory and learning is the authors' inference from that
expression pattern rather than a demonstrated function.
- reference: PMID:21484992
reference_title: "Deletion of the immunoglobulin domain of IL1RAPL1 results in nonsyndromic X-linked intellectual disability associated with behavioral problems and mild dysmorphism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have identified an additional two families with deletions of a
portion of the gene that give rise to cognitive impairment, as well as
some behavioral problems and mild dysmorphism.
explanation: >-
Documents phenotypic expansion beyond pure cognitive impairment,
supporting the subtype while qualifying the strictness of its
non-syndromic classification.
- name: MRX30
display_name: Intellectual disability, X-linked 30 (PAK3)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 30
term:
id: MONDO:0010361
label: intellectual disability, X-linked 30
genes:
- preferred_term: PAK3
term:
id: hgnc:8592
label: PAK3
description: >-
Truncating variants in PAK3 (p21-activated kinase) at Xq22, identified in
the multiplex MRX30 pedigree. PAK3 couples Rho family GTPases to actin
cytoskeletal reorganisation in postmitotic cortical and hippocampal
neurons, and this subtype anchors the Rho GTPase theme that recurs across
the class. MRI was normal in affected individuals - the imaging correlate
of a functional rather than structural lesion.
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Affected individuals in a multiplex pedigree with MRX (MRX30),
previously mapped to Xq22, show a point mutation in the PAK3
(p21-activated kinase) gene, which encodes a serine-threonine kinase.
explanation: >-
Establishes the PAK3 lesion defining the MRX30 subtype.
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MRI analysis showed no gross defects in brain development.
explanation: >-
Documents the absence of structural brain malformation that
distinguishes non-syndromic from malformative X-linked intellectual
disability.
- name: MRX41
display_name: Intellectual disability, X-linked 41 (GDI1)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 41
term:
id: MONDO:0010451
label: intellectual disability, X-linked 41
genes:
- preferred_term: GDI1
term:
id: hgnc:4226
label: GDI1
description: >-
Missense and null variants in GDI1, encoding alpha-GDI (Rab GDP
dissociation inhibitor), which recycles Rab GTPases for synaptic vesicle
traffic; the L92P allele reduces RAB3A binding and recycling. One of the
purest non-syndromic exemplars in the class - a large German multiplex
family had neither abnormal body measurements nor any other significant
clinical problem, and the authors concluded that a clinical diagnosis of
GDI1-associated disease is impossible.
evidence:
- reference: PMID:9620768
reference_title: "Mutations in GDI1 are responsible for X-linked non-specific mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have found mutations in the GDI1 gene (which encodes uGDI) in two
families affected with X-linked non-specific mental retardation. One of
the mutations caused a non-conservative substitution (L92P) which
reduced binding and recycling of RAB3A, the second was a null mutation.
explanation: >-
Establishes the GDI1 subtype and its Rab-recycling mechanism.
- reference: PMID:22002931
reference_title: "Novel GDI1 mutation in a large family with nonsyndromic X-linked intellectual disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the affected male family members had nonsyndromic intellectual
disability, that is, they had neither abnormal body measurements nor any
other significant clinical problems
explanation: >-
Confirms the strictly non-syndromic presentation of this subtype in an
independent multiplex family.
- reference: PMID:22002931
reference_title: "Novel GDI1 mutation in a large family with nonsyndromic X-linked intellectual disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The present family supports the lack of additional phenotypic features
in patients with GDI1 mutations, rendering a clinical diagnosis of
GDI1-associated XLID impossible.
explanation: >-
States the diagnostic consequence that defines the whole class - with no
distinguishing features, molecular testing rather than clinical
recognition is the only route to diagnosis.
- name: MRX58
display_name: Intellectual disability, X-linked 58 (TSPAN7/TM4SF2)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 58
term:
id: MONDO:0010266
label: intellectual disability, X-linked 58
genes:
- preferred_term: TSPAN7
term:
id: hgnc:11854
label: TSPAN7
description: >-
TSPAN7 (formerly TM4SF2) at Xp11.4, first implicated through an X;2
balanced translocation that disrupted the gene, then confirmed by point
variants in MRX families. Encodes a tetraspanin that complexes with
beta-1 integrins and is implicated in the control of neurite outgrowth,
contributing to the synapse-formation theme.
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here we show that the gene TM4SF2 at Xp11.4 is inactivated by the X
breakpoint of an X;2 balanced translocation in a patient with MR.
Further investigation led to identification of TM4SF2 mutations in 2 of
33 other MRX families.
explanation: >-
Establishes the TSPAN7/TM4SF2 subtype through two independent lines of
genetic evidence.
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
TM4SF2 encodes a member of the tetraspanin family of proteins, which are
known to contribute in molecular complexes including beta-1 integrins.
We speculate that through this interaction, TM4SF2 might have a role in
the control of neurite outgrowth.
explanation: >-
Assigns the subtype to the neurite-outgrowth/synapse-formation theme;
marked PARTIAL because the source explicitly frames the mechanism as
speculation.
- name: MRX9
display_name: Intellectual disability, X-linked 9 (FTSJ1)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 9
term:
id: MONDO:0010660
label: intellectual disability, X-linked 9
genes:
- preferred_term: FTSJ1
term:
id: hgnc:13254
label: FTSJ1
description: >-
Loss-of-function variants in FTSJ1, the human TRM7 homolog, which
2'-O-methylates positions C32 and G34 of the tRNA anticodon loop. Patient
cell lines almost completely lack Cm32 and Gm34 on tRNA-Phe. Places
translational fidelity - rather than synaptic structure - in the
mechanistic theme set for this class, and provides a directly measurable
molecular readout, unusual for non-syndromic intellectual disability.
evidence:
- reference: PMID:26310293
reference_title: "Defects in tRNA Anticodon Loop 2'-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability due to Mutations in FTSJ1."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Mutations in human FTSJ1, the likely TRM7 homolog, cause nonsyndromic
X-linked intellectual disability (NSXLID), but the role of FTSJ1 in tRNA
modification is unknown.
explanation: >-
Establishes FTSJ1 as a non-syndromic X-linked intellectual disability
gene.
- reference: PMID:26310293
reference_title: "Defects in tRNA Anticodon Loop 2'-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability due to Mutations in FTSJ1."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
we report that tRNA(Phe) from two genetically independent cell lines of
NSXLID patients with loss-of-function FTSJ1 mutations nearly completely
lacks Cm32 and Gm34 , and has reduced peroxywybutosine (o2yW37 )
explanation: >-
Provides the direct biochemical consequence of FTSJ1 loss in patient
cells, grounding the tRNA-modification mechanism.
- name: MRX63
display_name: Intellectual disability, X-linked 63 (ACSL4/FACL4)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked 63
term:
id: MONDO:0010313
label: intellectual disability, X-linked 63
genes:
- preferred_term: ACSL4
term:
id: hgnc:3571
label: ACSL4
description: >-
Null variants in ACSL4 (FACL4), encoding fatty acid-CoA ligase 4, mapped
to Xq22.3 by comparing deletion extents between contiguous-gene ATS-MR
patients and Alport-only patients. The first gene to link non-syndromic
intellectual disability to fatty-acid metabolism, and the subtype in which
complete X-inactivation skewing in carrier females is best documented.
evidence:
- reference: PMID:11889465
reference_title: "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here we report the identification of two point mutations, one missense
and one splice-site change, in the gene FACL4 in two families with
nonspecific mental retardation.
explanation: >-
Establishes the ACSL4/FACL4 subtype in non-specific (non-syndromic)
X-linked intellectual disability.
- reference: PMID:11889465
reference_title: "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
FACL4 is the first gene shown to be involved in nonspecific mental
retardation and fatty-acid metabolism.
explanation: >-
Places lipid metabolism in the mechanistic theme set for this class.
- name: FRAXE
display_name: FRAXE intellectual disability (AFF2/FMR2)
classification: molecular
subtype_term:
preferred_term: FRAXE intellectual disability
term:
id: MONDO:0010659
label: FRAXE intellectual disability
genes:
- preferred_term: AFF2
term:
id: hgnc:3776
label: AFF2
description: >-
CCG repeat expansion and consequent methylation-mediated silencing of AFF2
(FMR2) at the FRAXE folate-sensitive fragile site in Xq28. Mechanistically
the repeat-expansion member of the class and the closest non-syndromic
counterpart to fragile X syndrome, from which it is distinguished by a
milder cognitive phenotype without the fragile X somatic features. AFF2 is
among the genes found in non-syndromal families that were never assigned
an IDX number.
evidence:
- reference: PMID:8673086
reference_title: "Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mild mental retardation without consistent physical findings has been
found associated with expanded CCG repeats at FRAXE.
explanation: >-
Establishes both defining properties of this subtype in one statement:
the repeat-expansion mechanism, and the non-syndromic phenotype
(mild impairment WITHOUT consistent physical findings), which is what
qualifies it for this entry.
- reference: PMID:8673086
reference_title: "Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have identified a large gene (FMR2) transcribed distally from the CpG
island at FRAXE, and down-regulated by repeat expansion and methylation.
explanation: >-
Provides the methylation-mediated silencing mechanism asserted in this
subtype's description, which the sequence-variant evidence cited
elsewhere does not cover.
- reference: PMID:8673086
reference_title: "Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
FRAXA expansion results in fragile X syndrome due to down regulation of
expression of the FMR1 gene
explanation: >-
Grounds the contrast with fragile X syndrome drawn in this subtype's
description - the two are parallel folate-sensitive fragile-site
expansions with different genes and different phenotypic severity.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sequence variants in 11 genes (KLF8, AFF2, SLC6A8, NDUFA1, ALG13, SRPX2,
ATRX, NLGN3, FGDY, CDKL5, and NLGN4) have been found in families with
IDX but in whom IDX numbers were never assigned.
explanation: >-
Places AFF2 among the genes causing non-syndromal (IDX) X-linked
intellectual disability; marked PARTIAL because this passage concerns
sequence variants, a different mutational class from the repeat
expansion that defines the FRAXE subtype.
- name: ARX-related
display_name: Intellectual disability, X-linked, with or without seizures (ARX)
classification: molecular
subtype_term:
preferred_term: intellectual disability, X-linked, with or without seizures, ARX-related
term:
id: MONDO:0010317
label: intellectual disability, X-linked, with or without seizures, ARX-related
genes:
- preferred_term: ARX
term:
id: hgnc:18060
label: ARX
description: >-
The non-syndromic end of the ARX allelic series. ARX encodes an
Aristaless-related homeobox transcription factor expressed specifically in
telencephalon and ventral thalamus. Polyalanine-tract expansions and
certain missense alleles produce intellectual disability with or without
seizures and no detectable brain malformation, and account for nine
separately numbered nonsyndromal IDX families. Other alleles in the same
gene cause distinct syndromic entities (X-linked lissencephaly with
abnormal genitalia, Partington syndrome, West and Ohtahara syndromes,
Proud syndrome) that are deliberately NOT modelled here. This subtype is
therefore the worked example of why the syndromic/non-syndromic boundary
in this class is a property of the allele rather than of the gene.
evidence:
- reference: PMID:11971879
reference_title: "ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Inherited and de novo ARX mutations, including missense mutations and in
frame duplications/insertions leading to expansions of polyalanine
tracts in ARX, were found in nine familial and one sporadic case of MR.
explanation: >-
Establishes the ARX allelic spectrum, including the polyalanine
expansions associated with the milder non-syndromic end of the series.
- reference: PMID:11971879
reference_title: "ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The absence of detectable brain malformations in patients suggests that
ARX may have an essential role, in mature neurons, required for the
development of cognitive abilities.
explanation: >-
Confirms the non-syndromic, non-malformative presentation of these ARX
alleles, distinguishing them from the lissencephaly-causing alleles in
the same gene.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This is not the case for ARX variants, which have been found in the
disparate phenotypes of Partington syndrome, West syndrome, X-linked
lissencephaly with abnormal genitalia, hydranencephaly with abnormal
genitalia, Proud syndrome, Ohtahara syndrome as well as nonsyndromal
XLID (IDX 29, 32, 33, 36, 38, 43, 54, 76, 87).
explanation: >-
Documents that ARX spans both syndromic entities and nine separately
numbered nonsyndromal IDX families, which is the basis for modelling
only the nonsyndromal arm here.
- reference: PMID:31898314
reference_title: "Non-syndromic X linked intellectual disability: Current knowledge in light of the recent advances in molecular and functional studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
this classification is not always clear-cut because distinct variants in
several of these XLID genes can result in S-XLID as well as in NS-XLID
explanation: >-
Provides the general principle that licenses admitting one allelic arm
of a gene to this class while leaving its syndromic alleles to separate
entities - the reasoning applied to ARX here.
pathophysiology:
- name: X-Linked Gene Disruption
biological_scale: MOLECULAR
description: >-
Rare germline loss-of-function, hypomorphic, repeat-expansion, or
copy-number variants in any one of a large set of genes on the X
chromosome remove or reduce the activity of the encoded product in the
developing and mature brain. The class is clinically homogeneous but
genetically heterogeneous: variants at many different loci converge on the
same single clinical outcome, and each individual gene accounts for only a
small fraction of cases. The X chromosome is disproportionately
represented among intellectual-disability genes relative to its size.
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Nonsyndromic X-linked mental retardation (MRX) syndromes are clinically
homogeneous but genetically heterogeneous disorders, whose genetic bases
are largely unknown.
explanation: >-
States the defining architecture of the class - one phenotype, many
loci - which is why the numbered MRX series was defined by linkage
rather than by clinical features.
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At least five MRX genes have been identified by positional cloning, but
each accounts for only 0.5%-1.0% of MRX cases.
explanation: >-
Quantifies the per-gene contribution, establishing that no single gene
dominates this class.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The X-chromosome comprises only about 5% of the human genome but
accounts for about 15% of the genes currently known to be associated
with intellectual disability.
explanation: >-
Quantifies the disproportionate contribution of the X chromosome to
intellectual-disability genetics, the observation that motivated the
field.
downstream:
- target: Hemizygous Male Expression of the Mutant Allele
causal_link_type: DIRECT
description: >-
A variant on the single male X chromosome is expressed without a
compensating allele. Note this edge encodes a dosage/conditioning
relationship (hemizygosity is a property of male karyotype, not an event
caused by the variant) rather than a downstream biochemical step;
`DIRECT` is used because CausalLinkTypeEnum offers no conditioning
value.
- name: Hemizygous Male Expression of the Mutant Allele
biological_scale: CELLULAR
description: >-
Males carry one X chromosome, so a loss-of-function allele is expressed in
every cell with no second copy to buffer it. Heterozygous females are
mosaic, because random X-chromosome
inactivation silences one X per cell, so the mutant allele is expressed in
only a subset of cells; such carriers are typically unaffected or mildly
affected, and in several subtypes completely skewed X-inactivation
silences the mutant X entirely. This dosage asymmetry is the mechanistic
basis of the male excess observed among people with intellectual
disability, and the mosaicism is the principal obstacle to studying the
circuit pathophysiology in females.
evidence:
- reference: PMID:23871722
reference_title: "XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Because of the unbalanced sex ratio (1.3-1.4 to 1) observed in
intellectual disability (ID) and the identification of large ID-affected
families showing X-linked segregation, much attention has been focused
on the genetics of X-linked ID (XLID).
explanation: >-
Quantifies the male excess that hemizygous expression explains and that
motivated the field's focus on the X chromosome.
- reference: PMID:38424476
reference_title: "Overcoming genetic and cellular complexity to study the pathophysiology of X-linked intellectual disabilities."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
This mosaic expression produces substantial complexity, especially when
attempting to study the already complicated neural circuits that underly
behavior, thus impeding the understanding of disease-related
pathophysiology and the development of therapeutics.
explanation: >-
Establishes the consequence of female mosaicism for mechanistic study
and therapeutic development in this class. Tagged OTHER: the quoted
sentence is a methodological statement about the difficulty of studying
mosaic neural circuits, not a human clinical observation.
- reference: PMID:11889465
reference_title: "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All carrier females with either point mutations or genomic deletions in
FACL4 showed a completely skewed X-inactivation, suggesting that the
gene influences survival advantage.
explanation: >-
Demonstrates the complete X-inactivation skewing that spares carrier
females in this class.
downstream:
- target: Convergent Disruption of Neuronal Function
causal_link_type: DIRECT
description: >-
Loss of the gene product in neurons impairs the synaptic processes it
supports.
- name: Convergent Disruption of Neuronal Function
biological_scale: CELLULAR
description: >-
Although the causal genes do not share a single pathway, their products
fall repeatedly into a limited set of themes that converge on the same
functional endpoint: Rho GTPase signalling to the actin cytoskeleton
(PAK3), Rab-dependent synaptic vesicle recycling (GDI1), proposed roles in excitatory synapse
formation and neurite outgrowth (IL1RAPL1, TSPAN7 - both inferred rather
than directly demonstrated in the cited reports), tRNA anticodon-loop modification and translational fidelity
(FTSJ1), fatty-acid metabolism (ACSL4), Golgi/trans-Golgi-network pH
regulation and glycosylation (SLC9A7), transcriptional activation (AFF2,
silenced by the FRAXE repeat expansion), and telencephalic transcriptional
control (ARX). Most of these arms act on synapse formation, maintenance,
and plasticity, and synaptic convergence is the field's dominant framing
of the class. It is not, however, established for all of them: the
tRNA-modification (FTSJ1), fatty-acid (ACSL4), Golgi-pH (SLC9A7), and
transcriptional (AFF2) arms have documented molecular and cellular
consequences but no cited evidence of a synaptic endpoint, so the node is
deliberately named for neuronal rather than synaptic function. What is shared across every arm is that
convergence happens at the level of neuronal cell biology rather than
through a common molecular pathway - which is why no single
pathway-directed therapy addresses the class.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: chemical synaptic transmission
term:
id: GO:0007268
label: chemical synaptic transmission
modifier: DECREASED
- preferred_term: regulation of synapse structure or activity
term:
id: GO:0050803
label: regulation of synapse structure or activity
modifier: DECREASED
- preferred_term: Rho protein signal transduction
term:
id: GO:0007266
label: Rho protein signal transduction
modifier: DECREASED
- preferred_term: vesicle-mediated transport
term:
id: GO:0016192
label: vesicle-mediated transport
modifier: DECREASED
- preferred_term: tRNA modification
term:
id: GO:0006400
label: tRNA modification
modifier: DECREASED
- preferred_term: Golgi and post-Golgi pH regulation
term:
id: GO:0051453
label: regulation of intracellular pH
modifier: DECREASED
- preferred_term: glycosylation of exported cargo
term:
id: GO:0009101
label: glycoprotein biosynthetic process
modifier: DECREASED
- preferred_term: FMR2/AFF2-dependent transcriptional activation
term:
id: GO:0045893
label: positive regulation of DNA-templated transcription
modifier: DECREASED
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
PAK proteins are crucial effectors linking Rho GTPases to cytoskeletal
reorganization and to nuclear signalling.
explanation: >-
Establishes the Rho GTPase-to-cytoskeleton arm of the convergence.
Tagged OTHER: this is a background statement of established protein
function, not a result generated by the cited study.
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Signal transduction through Rho GTPases and PAK3 may be critical for
human cognitive function.
explanation: >-
Connects the Rho GTPase theme directly to the cognitive endpoint.
- reference: PMID:9620768
reference_title: "Mutations in GDI1 are responsible for X-linked non-specific mental retardation."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Rab GDP-dissociation inhibitors (GDI) are evolutionarily conserved
proteins that play an essential role in the recycling of Rab GTPases
required for vesicular transport through the secretory pathway.
explanation: >-
Establishes the vesicle-trafficking arm of the convergence. Tagged
OTHER: a background statement of established protein function rather
than a result of the cited study.
- reference: PMID:26310293
reference_title: "Defects in tRNA Anticodon Loop 2'-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability due to Mutations in FTSJ1."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
tRNA modifications are crucial for efficient and accurate protein
synthesis, and modification defects are frequently associated with
disease.
explanation: >-
Establishes the translational-fidelity arm of the convergence, which is
mechanistically distinct from the synaptic-structural arms. Tagged
OTHER: a general statement about tRNA biology rather than a result of
the cited study.
- reference: PMID:30335141
reference_title: "A recurrent missense variant in SLC9A7 causes nonsyndromic X-linked intellectual disability with alteration of Golgi acidification and aberrant glycosylation."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
These data implicate a crucial role for SLC9A7 in the regulation of
TGN/post-Golgi pH homeostasis and glycosylation of exported cargo, which
may underlie the cellular pathophysiology and neurodevelopmental
deficits associated with this particular nonsyndromic form of X-linked
ID.
explanation: >-
Establishes the Golgi-pH/glycosylation arm of the convergence, the most
recently characterised theme in this class.
- reference: PMID:11355014
reference_title: "Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Our results show that FMR2 is a potent transcription activator and that
its function is conserved.
explanation: >-
Establishes the transcriptional arm of the convergence and the molecular
function lost when the FRAXE expansion silences AFF2/FMR2. Tagged
IN_VITRO: the activation was measured in yeast and mammalian cell
reporter assays. GO:0045893 (positive regulation of DNA-templated
transcription) is used rather than the RNA-polymerase-II-specific term
because the reporter assays demonstrate transcription activation without
resolving promoter class.
- reference: PMID:11355014
reference_title: "Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Expansion of the FRAXE CCG repeat to a full mutation is associated with
methylation and transcriptional silencing of the FMR2 gene, and as a
consequence, mild-to-borderline mental retardation.
explanation: >-
Connects the loss of that transcriptional activity to the cognitive
endpoint, which is what places this arm on the convergence node rather
than leaving it as isolated protein biochemistry. Tagged OTHER rather
than HUMAN_CLINICAL: this is the abstract's opening background sentence,
and the study itself reports no human clinical data (its MeSH terms are
HeLa cells and Saccharomyces cerevisiae).
downstream:
- target: Impaired Synaptic Plasticity in Learning and Memory Circuits
causal_link_type: DIRECT
description: >-
Disrupted synapse formation, transmission, and recycling degrade
activity-dependent plasticity.
- name: Impaired Synaptic Plasticity in Learning and Memory Circuits
biological_scale: TISSUE
description: >-
The convergent synaptic lesion degrades activity-dependent plasticity in
the hippocampal and cortical circuits that support learning and memory.
Several causal genes are selectively or highly expressed in exactly these
structures - IL1RAPL1 in the postnatal hippocampal memory system, PAK3 in
postmitotic neurons of developing and postnatal cerebral cortex and
hippocampus, TSPAN7 in cerebral cortex and hippocampus - which is the
anatomical reason a diffuse molecular lesion produces a circumscribed
cognitive phenotype.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: cerebral cortex
term:
id: UBERON:0000956
label: cerebral cortex
- preferred_term: hippocampus
term:
id: UBERON:0002421
label: hippocampal formation
biological_processes:
- preferred_term: regulation of synaptic plasticity
term:
id: GO:0048167
label: regulation of synaptic plasticity
modifier: DECREASED
- preferred_term: dendritic spine morphogenesis
term:
id: GO:0060997
label: dendritic spine morphogenesis
modifier: DECREASED
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Immunofluorescence analysis showed that PAK3 protein is highly expressed
in postmitotic neurons of the developing and postnatal cerebral cortex
and hippocampus.
explanation: >-
Localises a causal gene product to the cortical and hippocampal circuits
that carry the cognitive phenotype. Tagged MODEL_ORGANISM: the
immunofluorescence was performed in animal tissue (the paper's MeSH
terms include Mice and Rats), not in patients.
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
RNA in situ hybridization showed that TM4SF2 is highly expressed in the
central nervous system, including the cerebral cortex and hippocampus.
explanation: >-
Independent confirmation that causal genes in this class are enriched in
the same learning-and-memory circuits. Tagged IN_VITRO: an in situ
hybridisation tissue-expression assay rather than a clinical
observation.
- reference: PMID:9620768
reference_title: "Mutations in GDI1 are responsible for X-linked non-specific mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our results show that both functional and developmental alterations in
the neuron may account for the severe impairment of learning abilities
as a consequence of mutations in GDI1, emphasizing its critical role in
development of human intellectual and learning abilities.
explanation: >-
Links the vesicle-recycling lesion to impaired learning through both
functional and developmental neuronal alterations.
downstream:
- target: Static Cognitive Impairment Without Structural Brain Malformation
causal_link_type: DIRECT
description: >-
Degraded plasticity in an anatomically normal brain manifests as
non-progressive intellectual disability.
- name: Static Cognitive Impairment Without Structural Brain Malformation
biological_scale: ORGANISM
description: >-
The endpoint of the class: non-progressive impairment of intellectual
functioning and adaptive behaviour in a brain that is structurally normal
on imaging and free of any consistently reproducible dysmorphic,
metabolic, or systemic sign. This is a mis-tuned rather than a mis-built
or damaged circuit, which is why brain MRI is characteristically
unremarkable and why - in the absence of any distinguishing feature -
molecular testing rather than clinical recognition is the only route to a
specific diagnosis. The class is conventionally described as static and
non-progressive, with developmental regression arguing against the
diagnosis; note that none of the evidence cited on this node speaks to
temporal course, so the staticity claim rests on clinical convention
rather than on a source quoted here.
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MRI analysis showed no gross defects in brain development.
explanation: >-
Documents the structurally normal brain that defines the non-syndromic
endpoint.
- reference: PMID:11971879
reference_title: "ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The absence of detectable brain malformations in patients suggests that
ARX may have an essential role, in mature neurons, required for the
development of cognitive abilities.
explanation: >-
Independent confirmation, in a second subtype, that the lesion is
functional rather than malformative.
- reference: PMID:22002931
reference_title: "Novel GDI1 mutation in a large family with nonsyndromic X-linked intellectual disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The present family supports the lack of additional phenotypic features
in patients with GDI1 mutations, rendering a clinical diagnosis of
GDI1-associated XLID impossible.
explanation: >-
States the diagnostic consequence of a phenotype with no distinguishing
features.
phenotypes:
- category: Neurologic
name: Intellectual disability
description: >-
Impaired intellectual functioning and adaptive behaviour, present as the
only consistent shared feature of the class. Severity spans mild to severe
depending on the gene and allele. Because the class aggregates many
individually rare gene-defined disorders, severity cannot be meaningfully
quantified at the group level.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:10471494
reference_title: "A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Non-overlapping deletions and a nonsense mutation in this gene were
identified in patients with cognitive impairment only.
explanation: >-
Documents cognitive impairment as the sole clinical feature, which is
the definition of the non-syndromic class. The VERY_FREQUENT band
follows from the phenotype being definitional rather than variable.
- reference: PMID:22002931
reference_title: "Novel GDI1 mutation in a large family with nonsyndromic X-linked intellectual disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the affected male family members had nonsyndromic intellectual
disability, that is, they had neither abnormal body measurements nor any
other significant clinical problems
explanation: >-
Independent confirmation that intellectual disability is the isolated
finding in a second subtype.
- category: Neurologic
name: Absence of distinctive clinical or biochemical features
description: >-
The defining negative finding of the class. Affected males have no
distinctive dysmorphic, malformative, or biochemical abnormality that is
reproducible across families, which is why the historical MRX families
were numbered by linkage interval rather than named for a phenotype, and
why molecular testing is the only route to a specific diagnosis. This is a
statement about consistency across cases, not about every individual
patient having isolated intellectual disability. No `phenotype_term` is
bound: this is a meta-statement about the ABSENCE of consistent
additional features, so binding it to HP:0001249 would both double-count
intellectual disability in graph export and assert the opposite of what
the entry means. HPO has no term for "no consistent additional feature".
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
They can be categorized into syndromic (MRXS) and nonspecific (MRX)
forms. In MRX forms, affected patients have no distinctive clinical or
biochemical features.
explanation: >-
States the defining negative criterion separating this class from the
syndromic (MRXS) forms.
- reference: PMID:31898314
reference_title: "Non-syndromic X linked intellectual disability: Current knowledge in light of the recent advances in molecular and functional studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Classically, XLID has been subdivided in syndromic intellectual
disability (S-XLID)-where intellectual disability (ID) is always
associated with other recognizable physical and/or neurological
features-and non-specific or non-syndromic intellectual disability
(NS-XLID) where the only common feature is ID.
explanation: >-
The dedicated NS-XLID review's definition of the class, stating
precisely that the defining property is ID being the only COMMON
feature - a statement about consistency across cases rather than about
isolation in each patient.
- category: Neurologic
name: Global developmental delay
description: >-
Delay across developmental domains in early childhood, the presentation
that precedes a formal diagnosis of intellectual disability before an IQ
can reliably be measured. More typical of paediatric case series; adult
historical families are usually described in terms of intellectual
disability directly. No evidence item is attached: none of the cited
sources reports a formal developmental-delay ascertainment in this class,
so the phenotype is recorded as clinical context only, per the evidence
SOP's option to keep the description without an evidence block rather
than attach a snippet that does not make the claim.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
- category: Neurologic
name: Delayed speech and language development
description: >-
Speech and language delay is common in several gene-defined forms,
including SLC9A7-related disease, but is strongly gene-dependent and not
universal across the class. No frequency band is recorded: the class
aggregates many gene-defined disorders and no source quantifies the
proportion affected at group level. No evidence item is attached either -
the speech phenotype in the SLC9A7 families is reported in the paper's full
text rather than its abstract, and the cached record for PMID:30335141 is
abstract-only, so there is no verifiable snippet to quote. Recorded as
clinical context pending a quotable source.
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
- category: Behavioral
name: Atypical behavior
description: >-
Behavioural problems and psychiatric features are reported in subsets of
families, most clearly documented in IL1RAPL1 deletion families. Their
presence marks the point at which a nominally non-syndromic subtype begins
to acquire additional features, and is one reason the class boundary is
regarded as blurred. No frequency band is recorded: the source reports two
families without a denominator, which does not support a quantitative
band. Autistic features are deliberately NOT claimed here even though they
fall under this term: they are recorded separately below under the child
term HP:0000729, on independent cohort evidence with its own denominator.
The parent and child entries are both retained because they rest on
different sources and make different claims - not to state the same
finding twice.
phenotype_term:
preferred_term: Atypical behavior
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: PMID:21484992
reference_title: "Deletion of the immunoglobulin domain of IL1RAPL1 results in nonsyndromic X-linked intellectual disability associated with behavioral problems and mild dysmorphism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have identified an additional two families with deletions of a
portion of the gene that give rise to cognitive impairment, as well as
some behavioral problems and mild dysmorphism.
explanation: >-
Documents behavioural problems in a subset of IL1RAPL1 families. No
frequency is asserted: this is a subset finding within two reported
families, not a quantified class-wide feature.
- category: Behavioral
name: Autistic behavior
description: >-
Autism spectrum features are reported in a substantial minority of
patients ascertained as suggestive non-syndromic XLID: nearly 30% of the
61 males in the Basque targeted-panel cohort, in a group explicitly
characterised in the same sentence as showing an unspecific (that is,
non-syndromic) phenotype. Read the denominator carefully - those 61 males
are a REFERRAL population selected on X-linked family history and normal
FMR1 testing, and only 16 of them received a candidate variant, so most of
the denominator carries no molecular XLID diagnosis. The figure therefore
describes the population in which this class is looked for, not a
genetically confirmed case series. This is the more specific sibling of
the `Atypical behavior` entry above, which carries the parent HPO term and
the independent IL1RAPL1-family evidence.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Autistic behavior
term:
id: HP:0000729
label: Autistic behavior
evidence:
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Most of the selected patients did not have relevant dysmorphic features,
confirming that they show an unspecific phenotype. However, autism
spectrum disorders were present in nearly 30% of them.
explanation: >-
Quantifies autistic features in a cohort selected for suggestive
non-syndromic XLID, in the same sentence in which the authors
characterise that cohort as phenotypically unspecific - so the figure is
drawn from the non-syndromic population this entry is about, though the
authors write "most", not all, of the patients lacked relevant
dysmorphic features. OCCASIONAL (5-29%) is the conservative reading of
"nearly 30%", which sits exactly on the OCCASIONAL/FREQUENT boundary;
the band would be FREQUENT if the true value were at or above 30%.
- category: Neurologic
name: Seizure
description: >-
Seizures occur in a minority of affected males - almost 15% of the
X-linked group in the Basque suggestive non-syndromic XLID cohort, that
group being the roughly 47 probands ascertained on X-linked family history
rather than the full 61-patient cohort - and are a designated variable
feature of the ARX-related subtype, which is named "with or without
seizures". The same referral-population caveat recorded on the
`Autistic behavior` entry applies. They are not a defining feature of the
class. When prominent and early, they should prompt consideration of the
syndromic ARX entities (West syndrome, Ohtahara syndrome) instead. Note
that the ARX-specific literature quote available here enumerates those
SYNDROMIC ARX entities, which this entry deliberately excludes, so it is
not attached: the frequency band rests on the cohort figure below, and the
ARX designation rests on the MONDO subtype label itself
("intellectual disability, X-linked, with or without seizures,
ARX-related", MONDO:0010317). The entry is therefore recorded at class
level rather than scoped to the ARX subtype, because the quantitative
evidence is a class-level cohort figure.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
phenotype_contexts:
- subtype: ARX-related
notes: >-
Seizures are a designated variable feature of this subtype, whose MONDO
label is "intellectual disability, X-linked, with or without seizures,
ARX-related" (MONDO:0010317). No frequency is recorded for the context:
the label establishes that seizures vary within the subtype without
quantifying them, and the only ARX-specific seizure quote available
enumerates the syndromic ARX entities this entry excludes. The context
exists so the subtype association survives structurally now that the
phenotype itself is recorded at class level on cohort evidence.
evidence:
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Almost 15% of the patients in the X-linked group also reported having
epilepsy.
explanation: >-
Quantifies epilepsy in the X-linked-family arm of a cohort selected for
suggestive non-syndromic XLID, supporting the OCCASIONAL band (5-29%).
genetic:
- name: IL1RAPL1
gene_term:
preferred_term: IL1RAPL1
term:
id: hgnc:5996
label: IL1RAPL1
relationship_type: CAUSATIVE
notes: >-
Interleukin-1 receptor accessory protein-like 1 at Xp22.1-21.3. Deletions
and nonsense variants cause non-syndromic X-linked intellectual
disability; the protein is highly expressed in postnatal hippocampus and
organises excitatory synapse formation.
evidence:
- reference: PMID:10471494
reference_title: "A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thorough investigation of an MRX critical region in Xp22.1-21.3 enabled
us to identify a new gene expressed in brain that is responsible for a
non-specific form of X-linked mental retardation.
explanation: >-
Establishes IL1RAPL1 as causal for the non-specific (non-syndromic)
form.
- name: PAK3
gene_term:
preferred_term: PAK3
term:
id: hgnc:8592
label: PAK3
relationship_type: CAUSATIVE
notes: >-
p21-activated serine-threonine kinase at Xq22. Truncating variants disrupt
kinase function and abolish Rho GTPase-to-cytoskeleton signalling in
postmitotic cortical and hippocampal neurons.
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The mutation produces premature termination, disrupting kinase function.
explanation: >-
Establishes the loss-of-function mechanism of the causal PAK3 allele.
- name: GDI1
gene_term:
preferred_term: GDI1
term:
id: hgnc:4226
label: GDI1
relationship_type: CAUSATIVE
notes: >-
Rab GDP-dissociation inhibitor alpha. Missense (L92P) and null alleles
impair recycling of RAB3A and synaptic vesicle traffic. Associated with a
strictly non-syndromic phenotype across independent families.
evidence:
- reference: PMID:9620768
reference_title: "Mutations in GDI1 are responsible for X-linked non-specific mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
One of the mutations caused a non-conservative substitution (L92P) which
reduced binding and recycling of RAB3A, the second was a null mutation.
explanation: >-
Characterises both the missense and null mechanisms at this locus.
- name: TSPAN7
gene_term:
preferred_term: TSPAN7
term:
id: hgnc:11854
label: TSPAN7
relationship_type: CAUSATIVE
notes: >-
Tetraspanin 7 (formerly TM4SF2) at Xp11.4, implicated by a disrupting X;2
translocation breakpoint and by point variants in MRX families.
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Further investigation led to identification of TM4SF2 mutations in 2 of
33 other MRX families.
explanation: >-
Provides the independent point-variant evidence beyond the index
translocation.
- name: FTSJ1
gene_term:
preferred_term: FTSJ1
term:
id: hgnc:13254
label: FTSJ1
relationship_type: CAUSATIVE
notes: >-
tRNA 2'-O-methyltransferase, the human TRM7 homolog. Loss-of-function
alleles abolish Cm32 and Gm34 modification of the tRNA anticodon loop; a
p.A26P missense allele produces a selective Gm34 defect, giving an
allele-specific biochemical readout.
evidence:
- reference: PMID:26310293
reference_title: "Defects in tRNA Anticodon Loop 2'-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability due to Mutations in FTSJ1."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Additionally, tRNA(Phe) from an NSXLID patient with a novel
FTSJ1-p.A26P missense allele specifically lacks Gm34 , but has normal
levels of Cm32 and o2yW37 .
explanation: >-
Demonstrates allele-specific biochemical consequences at this locus.
- name: ACSL4
gene_term:
preferred_term: ACSL4
term:
id: hgnc:3571
label: ACSL4
relationship_type: CAUSATIVE
notes: >-
Fatty acid-CoA ligase 4 (FACL4) at Xq22.3. Missense and splice-site null
alleles reduce enzymatic activity in patient lymphoblastoid lines. Mapped
by narrowing the ATS-MR contiguous-gene deletion interval to roughly
380 kb.
evidence:
- reference: PMID:11889465
reference_title: "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Analysis of enzymatic activity in lymphoblastoid cell lines from
affected individuals of both families revealed low levels compared with
normal cells, indicating that both mutations are null mutations.
explanation: >-
Provides the functional confirmation that both alleles are null.
- name: ARX
gene_term:
preferred_term: ARX
term:
id: hgnc:18060
label: ARX
relationship_type: CAUSATIVE
notes: >-
Aristaless-related homeobox transcription factor with telencephalon- and
ventral-thalamus-restricted expression. Polyalanine expansions and certain
missense alleles give the non-syndromic phenotype modelled here; other
alleles in the same gene cause distinct syndromic entities.
evidence:
- reference: PMID:11971879
reference_title: "ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In contrast to other genes involved in XLMR, ARX expression is specific
to the telencephalon and ventral thalamus.
explanation: >-
Characterises the restricted expression domain that distinguishes ARX
from the broadly expressed genes in this class.
- name: AFF2
gene_term:
preferred_term: AFF2
term:
id: hgnc:3776
label: AFF2
relationship_type: CAUSATIVE
notes: >-
AF4/FMR2 family member 2 at the FRAXE folate-sensitive fragile site in
Xq28. Silenced by CCG repeat expansion and methylation, giving the
repeat-expansion route into this class. Found in non-syndromal (IDX)
families that were never assigned an IDX number.
evidence:
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sequence variants in 11 genes (KLF8, AFF2, SLC6A8, NDUFA1, ALG13, SRPX2,
ATRX, NLGN3, FGDY, CDKL5, and NLGN4) have been found in families with
IDX but in whom IDX numbers were never assigned.
explanation: >-
Places AFF2 among the genes causing non-syndromal X-linked intellectual
disability.
- name: SLC9A7
gene_term:
preferred_term: SLC9A7
term:
id: hgnc:17123
label: SLC9A7
relationship_type: CAUSATIVE
notes: >-
Alkali cation/proton exchanger (NHE7) at Xp11.3, resident in the
trans-Golgi network and post-Golgi vesicles. A recurrent p.Leu515Phe
missense variant in two unrelated multigenerational families alkalinises
the TGN and impairs N-glycosylation of exported cargo, with an abnormal
serum transferrin glycosylation profile in patients. The most recently
characterised mechanistic theme in this class; not curated as a formal
subtype here because a corresponding MONDO descendant term was not
confirmed.
evidence:
- reference: PMID:30335141
reference_title: "A recurrent missense variant in SLC9A7 causes nonsyndromic X-linked intellectual disability with alteration of Golgi acidification and aberrant glycosylation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report two unrelated families with multigenerational nonsyndromic
intellectual disability (ID) segregating with a recurrent de novo
missense variant (c.1543C>T:p.Leu515Phe) in the alkali cation/proton
exchanger gene SLC9A7 (also commonly referred to as NHE7).
explanation: >-
Establishes SLC9A7 as causal for a non-syndromic form in two independent
families.
- reference: PMID:30335141
reference_title: "A recurrent missense variant in SLC9A7 causes nonsyndromic X-linked intellectual disability with alteration of Golgi acidification and aberrant glycosylation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mass spectrometry analysis of patient sera also revealed an abnormal
N-glycosylation profile for transferrin, a clinical diagnostic marker
for congenital disorders of glycosylation.
explanation: >-
Provides a measurable biochemical readout for this form, unusual in a
class defined by the absence of biochemical features.
diagnosis:
- name: Fragile X (FMR1) repeat testing
description: >-
Sizing of the FMR1 CGG trinucleotide repeat, performed before or alongside
sequencing. It is separated from the sequencing entry below because it is a
mechanically distinct assay: a repeat expansion is not reliably called by
exome or panel sequencing, so a normal sequencing result does not exclude
fragile X syndrome. Fragile X is the most common single XLID entity, and
excluding it is the conventional first step in a male with intellectual
disability and a suggestive X-linked family history - in the Basque
targeted-panel cohort, every one of the 61 patients had already been
referred for FMR1 testing and shown a normal repeat number before
enrolment.
diagnosis_term:
preferred_term: Molecular Analysis
term:
id: NCIT:C19770
label: Molecular Analysis
evidence:
- reference: PMID:22482801
reference_title: "Fragile X and X-linked intellectual disability: four decades of discovery."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Over 150 syndromes, the most common of which is the fragile X syndrome,
have been described.
explanation: >-
Establishes fragile X syndrome as the most common of the XLID syndromes,
which is why its exclusion is the conventional first diagnostic step in
this population. Tagged OTHER: the source is a historical review and the
sentence summarises the field rather than reporting a clinical series.
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These patients were initially referred to the molecular genetics
laboratory to exclude Fragile X Syndrome.
explanation: >-
Documents FMR1 testing as the referral-level first step preceding
sequencing in a suggestive non-syndromic XLID cohort.
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All 61 patients had normal G-banded karyotype and showed normal FMR1
trinucleotide repeat numbers.
explanation: >-
Documents that a normal FMR1 repeat number was, in this cohort, already
established before enrolment - so fragile X exclusion preceded the
non-syndromic XLID workup rather than running alongside it. The
generalisation to practice is the entry's own inference from the
referral pattern, not a claim of the quoted sentence.
- name: Molecular genetic testing (exome or genome sequencing)
description: >-
Because affected individuals have no distinguishing clinical features, a
specific diagnosis cannot be reached by examination and requires parallel
molecular testing of all known intellectual-disability genes. The
contemporary workup is clinical evaluation with a family pedigree,
fragile X (FMR1) testing (recorded as its own entry above), chromosomal
microarray, and exome or genome sequencing with segregation analysis; of
these, only fragile X exclusion and panel sequencing with segregation are
covered by the evidence cited here, the remainder - chromosomal microarray
in particular - reflecting standard practice. Targeted XLID panels
retain a role in pedigrees with suggestive X-linked family history: in one
cohort of 61 unrelated males with suggestive non-syndromic XLID and
negative fragile X testing, an 82-gene panel identified 17 candidate
variants in 16 patients.
diagnosis_term:
preferred_term: Genetic Testing
term:
id: NCIT:C15709
label: Genetic Testing
evidence:
- reference: PMID:22002931
reference_title: "Novel GDI1 mutation in a large family with nonsyndromic X-linked intellectual disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thus, this family not only broadens the spectrum of GDI1 mutations but
also emphasizes the need for parallel testing of all known genes
associated with ID in patients with an unspecific phenotype.
explanation: >-
States the diagnostic strategy the class requires and the reason for it.
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We have performed targeted next-generation sequencing of 82 XLID genes
on 61 non-related male patients with suggestive non-syndromic XLID.
These patients were initially referred to the molecular genetics
laboratory to exclude Fragile X Syndrome.
explanation: >-
Documents the cohort design and the position of targeted panels after
fragile X exclusion in this population.
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sequencing data analysis identified 17 candidate variants in 16
patients.
explanation: >-
Quantifies the diagnostic yield of a targeted panel in a suggestive
non-syndromic XLID cohort.
- name: Brain MRI
description: >-
Characteristically unremarkable. Its role here is exclusionary - normal
imaging supports a non-syndromic, non-malformative diagnosis and argues
against the malformative X-linked entities (for example ARX-related
lissencephaly) that enter the differential.
diagnosis_term:
preferred_term: Magnetic Resonance Imaging
term:
id: NCIT:C16809
label: Magnetic Resonance Imaging
evidence:
- reference: PMID:9731525
reference_title: "PAK3 mutation in nonsyndromic X-linked mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MRI analysis showed no gross defects in brain development.
explanation: >-
Documents the normal imaging expected in this class.
- name: X-chromosome inactivation studies in female relatives
description: >-
Assessment of X-inactivation skewing in mothers and female relatives.
Extreme skewing supports an X-linked cause and, in cohorts of females with
idiopathic intellectual disability, enriches for pathogenic findings on
subsequent sequencing - 11 of 136 informative women showed at least 90%
skewing, and exome sequencing found pathogenic variants in 8 of those 11.
Note that those variants were dominant and included autosomal genes, so
skewing is an ascertainment aid toward a genetic diagnosis generally, not
a diagnostic criterion for this class.
diagnosis_term:
preferred_term: Molecular Analysis
term:
id: NCIT:C19770
label: Molecular Analysis
evidence:
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
and 14 male patients with ID and affected brothers whose mothers show
skewed X-inactivation
explanation: >-
Documents maternal X-inactivation skewing used as an ascertainment
criterion for suspected X-linked intellectual disability.
- reference: PMID:36943625
reference_title: "Skewed X-chromosome Inactivation in Women with Idiopathic Intellectual Disability is Indicative of Pathogenic Variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among the 136 patients who were informative, 11 (8%) presented with
extreme or total XCI skewing (>= 90%), which was significantly higher
than expected by chance.
explanation: >-
Quantifies the enrichment of extreme X-inactivation skewing in women
with idiopathic intellectual disability.
- reference: PMID:36943625
reference_title: "Skewed X-chromosome Inactivation in Women with Idiopathic Intellectual Disability is Indicative of Pathogenic Variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All variants were mapped to ID-related genes with dominant phenotypes:
four variants in the X-linked genes DDX3X (an XCI escape gene; two
cases), WDR45, and PDHA1, and four variants in the autosomal genes
KCNB1, CTNNB1, YY1, and ANKRD11.
explanation: >-
Important qualification, and the reason this is PARTIAL for this entry:
half the variants recovered by the skewing-guided strategy were
autosomal, so the yield is not specific to X-linked - let alone
non-syndromic X-linked - intellectual disability.
treatments:
- name: Genetic Counseling
description: >-
Establishing a molecular diagnosis enables carrier detection in female
relatives and informs recurrence-risk counselling and reproductive
options, including prenatal diagnosis and preimplantation genetic testing
where a familial pathogenic variant is known. Because the mode of
inheritance is X-linked, carrier females have a 50% chance of transmitting
the allele to each child, and the counselling yield is high in the large
multiplex pedigrees characteristic of this class.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
therapeutic_modality: OTHER
evidence:
- reference: PMID:22482801
reference_title: "Fragile X and X-linked intellectual disability: four decades of discovery."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At the same time, it has improved the clinical diagnosis of XLID and
allowed for carrier detection and prevention strategies through gamete
donation, prenatal diagnosis, and genetic counseling.
explanation: >-
Documents genetic counselling and carrier detection as the established
clinical payoff of molecular diagnosis in this class.
- name: Supportive Care
description: >-
No disease-modifying therapy is established for this class. Management is
supportive and individualised: developmental, educational, speech-language,
occupational, physical, and behavioural interventions, with psychiatric and
antiseizure treatment where indicated. This entry carries the umbrella
claim and the evidence that care is supportive only; the two most
consistently named allied-health modalities are additionally recorded as
their own NCIT-coded entries below, for queryability. Because management is
phenotype- and gene-specific, the evidence base is largely extrapolated
from broader neurodevelopmental care rather than generated for this class.
Gene therapy, selective X-reactivation, and synapse- or circuit-directed
interventions remain experimental and are mostly not specific to this
class.
treatment_term:
preferred_term: Supportive Care
term:
id: NCIT:C15747
label: Supportive Care
therapeutic_modality: OTHER
evidence:
- reference: PMID:38424476
reference_title: "Overcoming genetic and cellular complexity to study the pathophysiology of X-linked intellectual disabilities."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Here, we review a few selected X-linked forms of ID that predominantly
affect heterozygous females and the current obstacles for developing
effective therapies for such disorders.
explanation: >-
Documents that effective disease-modifying therapies for X-linked
intellectual disability remain obstructed and under development, which
is why care is supportive. Tagged OTHER for the same reason as the
hemizygous-expression node: the sentence states the scope of a review
rather than reporting a clinical observation.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The progress in identifying genetic and genomic alterations associated
with XLID has not been matched with insights that improve the
clinician's ability to form differential diagnoses, that bring into view
the possibility of curative therapies for patients
explanation: >-
States explicitly that gene discovery in this class has not yet
translated into curative therapy, grounding the supportive-care-only
position.
- name: Speech and Language Therapy
description: >-
Speech-language intervention, including augmentative and alternative
communication where speech is absent or limited, is a standard component of
multidisciplinary care and is tied to the group rather than to any single
causal gene. No evidence block is attached, and this is deliberate: none
of the references cached for this entry mentions speech-language therapy
at all - including the two the deep-research report attributed the
modality list to, one of which is cached as full text - so there is no
quotable source, and the DR report over-attributed the enumeration.
Recorded as a queryable NCIT-coded entry under the supportive-care
umbrella above, not as an evidenced claim.
treatment_term:
preferred_term: speech and language therapy
term:
id: NCIT:C159273
label: Speech Language Therapy
therapeutic_modality: BEHAVIORAL
- name: Occupational Therapy
description: >-
Occupational therapy addressing adaptive, motor, and daily-living skills,
likewise tied to the group rather than to a specific gene. As with speech
and language therapy, no evidence block is attached because no cached
reference for this entry mentions the modality; the entry exists to make
it queryable rather than to assert a class-specific evidence base.
treatment_term:
preferred_term: occupational therapy
term:
id: NCIT:C121351
label: Occupational Therapy
therapeutic_modality: BEHAVIORAL
differential_diagnoses:
- name: Syndromic X-linked intellectual disability (MRXS)
description: >-
The primary differential. MRXS entities share X-linked inheritance and
intellectual disability but add distinguishing physical, neurological, or
biochemical features. The boundary is explicitly regarded as blurred and
sometimes arbitrary: 28 of the numbered non-syndromal (IDX) genes are also
associated with XLID syndromes. Separately curated dismech entries in this
family (Claes-Jensen, Siderius, Shashi, Turner type) are deliberately not
modelled as subtypes here.
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
They can be categorized into syndromic (MRXS) and nonspecific (MRX)
forms. In MRX forms, affected patients have no distinctive clinical or
biochemical features.
explanation: >-
States the criterion that separates the two classes.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Twenty-eight of the “IDX genes” in Figure 3 have also been associated
with XLID syndromes.
explanation: >-
Quantifies the overlap between the two classes at the gene level,
showing the differential is often not resolvable by gene identity alone.
- name: Fragile X syndrome
description: >-
The most common syndromic XLID entity and the standard exclusion before
this diagnosis is entertained - patients in non-syndromic XLID cohorts are
typically referred after negative FMR1 testing. Distinguished by the
characteristic somatic features and the FMR1 CGG expansion.
evidence:
- reference: PMID:31906484
reference_title: "Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These patients were initially referred to the molecular genetics
laboratory to exclude Fragile X Syndrome.
explanation: >-
Documents fragile X exclusion as the standard first step before
non-syndromic XLID is pursued.
- name: Autosomal recessive non-syndromic intellectual disability
description: >-
Clinically indistinguishable in an isolated male. Distinguished by
pedigree structure (affected siblings of both sexes, parental
consanguinity, no X-linked segregation) and ultimately by molecular
testing.
- name: Autosomal dominant non-syndromic intellectual disability
description: >-
The dominant class, in which sporadic de novo heterozygous variants in
constraint-intolerant autosomal genes predominate. In a sporadic male with
no family history this is now a more likely explanation than a novel
X-linked cause, a reversal of the pre-exome-era prior.
discussions:
- discussion_id: questioned_xlid_gene_assignments
kind: KNOWLEDGE_GAP
prompt: >-
Which of the genes historically assigned to non-syndromic X-linked
intellectual disability are genuinely causal, given that many were
nominated from small families before large population control sets were
available?
attaches_to:
- pathophysiology#X-Linked Gene Disruption
rationale: >-
Gene lists for this class carry an unusual historical liability. Genes
were nominated by linkage in individual families at a time when systematic
sequencing of control X chromosomes was not possible, so rare
non-disease-causing variants could not be excluded. When 106 proposed XLID
genes were reassessed against 10,563 control X chromosomes from the NHLBI
Exome Sequencing Project, ten were specifically questioned because
truncating or previously published variants occurred at appreciable
frequency in controls, and a further fifteen were flagged as requiring
replication. The 2017 authoritative update revisited those 25 challenged
genes: none of the five highly questionable assignments has been
confirmed, only ATP6AP2 of the five questionable ones has been confirmed,
and additional cases have been published for seven of the fifteen needing
replication - leaving 17 of the 25 still unresolved. This directly affects
curation of this entry: AGTR2 in particular is frequently cited in older
reviews as a non-syndromic XLID gene and is among the questioned set, so
it is deliberately not modelled as a subtype here. Any gene list for this
class drawn from literature predating the reassessment should be treated
as provisional.
proposed_experiments:
- experiment_id: reassess_questioned_xlid_genes_gnomad
name: Re-evaluation of questioned XLID genes against contemporary population databases
description: >-
Repeat the control-frequency reassessment against gnomAD-scale
population data, which offers far more X chromosomes than the NHLBI
cohort, and combine with independent replication cohorts and functional
assays for the genes still flagged as requiring replication.
evidence:
- reference: PMID:23871722
reference_title: "XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We used this NHLBI cohort to systematically reassess the implication of
106 genes proposed to be involved in monogenic forms of XLID. We
particularly question the implication in XLID of ten of them (AGTR2,
MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41, and
ZNF81), in which truncating variants or previously published mutations
are observed at a relatively high frequency within this cohort.
explanation: >-
Names the specific genes whose causal role in this class is in doubt,
including AGTR2, ZNF41, and ARHGEF6, which appear in older MRX gene
lists.
- reference: PMID:23871722
reference_title: "XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Nonetheless, the boundary between true mutations and rare
non-disease-causing variants often remains elusive. The sequencing of a
large number of control X chromosomes, required for avoiding
false-positive results, was not systematically possible in the past.
explanation: >-
Explains the methodological reason this class accumulated
false-positive gene assignments.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Of the 15 assignments in need of replication, additional cases with
MAOA, HCFC1, CCDC22, CNKSR2, KIAA2022, NAA10 and SHROOM4 sequence
variants have now been published, leaving 17 of the 25 challenged genes
unresolved.
explanation: >-
Gives the current resolution status of the challenged genes - the direct
measure of how much of this gap remains open.
- reference: PMID:19377476
reference_title: "A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The study has, however, also highlighted issues confronting whole-genome
sequencing screens, including the observation that loss of function of
1% or more of X-chromosome genes is compatible with apparently normal
existence.
explanation: >-
Provides the independent, orthogonal reason gene attribution is hard in
this class: X-chromosome loss-of-function is tolerated more often than
assumed, so a truncating variant is not self-evidently causal.
- discussion_id: syndromic_nonsyndromic_boundary_stability
kind: KNOWLEDGE_GAP
prompt: >-
Is "non-syndromic" a stable property of a gene, or an artefact of limited
phenotyping and allele sampling?
attaches_to:
- pathophysiology#Static Cognitive Impairment Without Structural Brain Malformation
rationale: >-
The class boundary moves in both directions and is explicitly described in
the authoritative update as blurred, sometimes arbitrary, and difficult to
defend biologically - retained mainly for historical continuity. IL1RAPL1
was reported as causing cognitive impairment only, but later families
showed behavioural problems and mild dysmorphism. ARX shows the converse
within a single gene: polyalanine expansions give a non-syndromic
phenotype across nine numbered IDX families while other alleles cause
lissencephaly with abnormal genitalia, Partington, West, and Ohtahara
syndromes. Twenty-eight IDX genes are also associated with XLID syndromes.
Whether a given gene stays in this class therefore depends on how many
patients have been phenotyped, how deeply, and which alleles they carry -
not on a fixed biological property. This matters for the KB because
membership of this entry is provisional for several subtypes, and it is
the reason FGD1, ZDHHC9, and OPHN1, which are named in older non-syndromic
gene lists but map to explicitly syndromic MONDO entities, are excluded
here.
evidence:
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Even though the line dividing the two classes is blurred, sometimes
arbitrary and difficult to defend from a biological standpoint, it has
by now acquired quasi-historical value and deserves to be retained.
explanation: >-
The authoritative statement that the syndromic/non-syndromic distinction
is retained for historical rather than biological reasons - the core of
this knowledge gap.
- reference: PMID:31898314
reference_title: "Non-syndromic X linked intellectual disability: Current knowledge in light of the recent advances in molecular and functional studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Nevertheless, new advances on the study of these entities have showed
that this classification is not always clear-cut because distinct
variants in several of these XLID genes can result in S-XLID as well as
in NS-XLID.
explanation: >-
States the allele-level mechanism behind the unstable boundary directly:
it is the variant, not the gene, that determines which class a case
falls into. This is the evidential basis for admitting only the
non-syndromic arm of the ARX allelic series.
- reference: PMID:21484992
reference_title: "Deletion of the immunoglobulin domain of IL1RAPL1 results in nonsyndromic X-linked intellectual disability associated with behavioral problems and mild dysmorphism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Our clinical findings better delineate the phenotypic spectrum
associated with IL1RAPL1 mutations.
explanation: >-
Demonstrates phenotypic expansion of a subtype originally described as
purely non-syndromic.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This is not the case for ARX variants, which have been found in the
disparate phenotypes of Partington syndrome, West syndrome, X-linked
lissencephaly with abnormal genitalia, hydranencephaly with abnormal
genitalia, Proud syndrome, Ohtahara syndrome as well as nonsyndromal
XLID (IDX 29, 32, 33, 36, 38, 43, 54, 76, 87).
explanation: >-
Documents the allelic heterogeneity within ARX that places non-syndromic
and severely syndromic phenotypes in the same gene.
- discussion_id: nonsyndromic_xlid_group_level_prevalence
kind: KNOWLEDGE_GAP
prompt: >-
What is the population prevalence of non-syndromic X-linked intellectual
disability as distinct from X-linked intellectual disability as a whole?
attaches_to:
- pathophysiology#X-Linked Gene Disruption
rationale: >-
The prevalence figures recorded on this entry - approximately 1 in 600
males, and 5-10% of intellectual disability in males - are for X-linked
intellectual disability overall, syndromic and non-syndromic combined. No
robust population prevalence or incidence exists for the non-syndromic
class alone, because it aggregates many individually rare gene-defined
disorders whose ascertainment has historically depended on the
availability of large multiplex pedigrees. This is a genuine measurement
gap rather than a curation omission, and the recorded rates should not be
presented as if MONDO:0019181 were a uniform entity with its own
prevalence.
proposed_experiments:
- experiment_id: population_scale_nsxlid_prevalence
name: Population-scale sequencing estimate of non-syndromic XLID prevalence
description: >-
Estimate class prevalence from unselected population-scale exome or
genome cohorts with linked phenotype data, ascertaining on validated
causal variants in confirmed non-syndromic XLID genes rather than on
pedigree structure, which avoids the multiplex-family ascertainment bias
that inflates familial forms.
evidence:
- reference: PMID:10655063
reference_title: "A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
X-linked forms of mental retardation (MR) affect approximately 1 in 600
males and are likely to be highly heterogeneous.
explanation: >-
The available rate is explicitly for X-linked forms as a whole, not the
non-syndromic class, which is the substance of this gap.
- reference: PMID:29696803
reference_title: "X-linked intellectual disability update 2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
As to the families with nonsyndromal XLID which have received IDX
numbers, their total is currently 105 (Figure 3). For 67 of these
families, the genes have been cloned, 33 have been mapped but the genes
have not been identified and 5 have reserved IDX numbers (IDX8, 50, 69,
83 and 86) but have not been published.
explanation: >-
Shows the class is enumerated by ascertained families rather than by
population sampling, which is why no population prevalence exists for
it.
datasets:
- accession: geo:GSE179384
title: The ribose methylation enzyme FTSJ1 has a conserved role in neuron morphology and learning performance
data_type: BULK_RNA_SEQ
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 9
genes:
- preferred_term: FTSJ1
term:
id: hgnc:13254
label: FTSJ1
publication: PMID:36720500
notes: >-
Human lymphoblastoid material from patients with FTSJ1 loss of function,
supporting the MRX9 subtype and the tRNA-modification arm of the
convergence node. Selected by relevance triage from the dataset-discovery
candidates as the only DIRECT (disease-named, human, primary-material)
hit; the remaining candidates were GENE_ONLY matches whose biology is
unrelated to this disease (for example TSPAN7 in pancreatic beta-cell
exocytosis, GDI1 in yeast Ypt1 trafficking) and were rejected. No
evidence block is attached, per the dataset-curation SOP.
notes: >-
Scope decisions for this entry, recorded so they are auditable.
Included as subtypes: IL1RAPL1 (MRX21), PAK3 (MRX30), GDI1 (MRX41), TSPAN7
(MRX58), FTSJ1 (MRX9), ACSL4 (MRX63), AFF2 (FRAXE), and the non-syndromic
arm of the ARX allelic series. Each maps to a MONDO term that is a
descendant of MONDO:0019181 and each has a primary publication describing a
non-syndromic presentation.
Deliberately excluded: FGD1 (maps to Aarskog-Scott syndrome,
MONDO:0010589 - classic syndromic facial/skeletal/genital dysmorphism),
ZDHHC9 (maps to syndromic X-linked intellectual disability, Raymond type,
MONDO:0010427 - "syndromic" appears in the MONDO label itself), and OPHN1
(maps to X-linked intellectual disability-cerebellar hypoplasia syndrome,
MONDO:0010337). All three appear in older non-syndromic gene lists but
resolve to syndromic MONDO entities, and the curation issue for this entry
specifies that syndromic X-linked entries stay separate. RLIM/MRX61 is also
excluded: although MONDO:0010506 sits under this root, the 2018 clinical
series (PMID:29728705) describes it as a syndromic X-linked intellectual
disability and behaviour disorder, so its placement is unresolved.
AGTR2 is excluded on evidence grounds rather than scope grounds - it is one
of the ten genes whose involvement in XLID was specifically questioned
against 10,563 control X chromosomes, and it remains among the unresolved
set as of the 2017 update (see the questioned_xlid_gene_assignments
discussion).
SLC9A7 is curated under `genetic:` rather than as a formal subtype: the
evidence for a non-syndromic presentation is strong (PMID:30335141), but a
corresponding MONDO descendant term of MONDO:0019181 was not confirmed
during curation. It should be promoted to a subtype if one is identified.
MONDO lists over 50 descendants of MONDO:0019181, most of them numbered MRX
entries whose causal gene is not recorded in MONDO. The subtypes modelled
here are the well-characterised, gene-anchored members; the entry is not
intended to enumerate the full numbered series. For orientation, the 2017
update counts 105 non-syndromal families with IDX numbers, 67 of them with a
cloned gene, against 141 XLID genes overall.
This entry completes the non-syndromic intellectual-disability trio with
Autosomal_Dominant_Non-Syndromic_Intellectual_Disability and
Autosomal_Recessive_Non-Syndromic_Intellectual_Disability. A Grouping
uniting the three would be a reasonable follow-up.
No GeneReviews chapter exists for the umbrella non-syndromic X-linked
intellectual disability class; GeneReviews coverage in this space is
organised per syndromic gene (searched 2026-08-12), so the GeneReviews
phenotype baseline does not apply to this entry.
Deep research was run with Edison (falcon). The NEC preflight returned SKIP
because MONDO records no causal gene for this umbrella term; the manual
fallback check was performed - the report's most-discussed genes (SLC9A7,
IQSEC2, SLC6A8, FMR1, HCFC1) are all genuine X-linked
intellectual-disability genes and the report is unambiguously about this
entity, so no Named Entity Confusion was found. Every PMID and snippet used
from the report was independently fetched and verified against the cached
reference record before use. Most of those records are abstracts; four
snippets from PMID:31906484 quote its body text, which is present because
that record is cached as full text.
No `clinical_trials:` block is recorded because the search returns nothing
for this class. A ClinicalTrials.gov query on the condition "X-linked
intellectual disability" (API v2, run 2026-08-12) returns trials in other
entities - predominantly syndromic ones such as Rett syndrome, fragile X
syndrome and the mucopolysaccharidoses, alongside unrelated hits - and no
disease-modifying interventional trial in non-syndromic XLID, which matches
the deep-research report's own negative finding. The two studies that do
name this population are phenotyping and natural-history research rather
than treatment: NCT02854956 (clinical phenotyping and characterisation of
neural networks in X-linked mental retardation - registered as
INTERVENTIONAL, but the intervention is the phenotyping protocol, not a
therapy; status UNKNOWN) and NCT06500260 (CNKSR2 natural-history study,
observational). Both were verified against the registry. Listing either as a treatment would
misrepresent them, so the negative result is recorded here instead.
Two DR-surfaced phenotypes are deliberately not modelled. Hypotonia
(HP:0001252) and muscle weakness (HP:0001324) are reported in the SLC9A7
families, but only in that paper's full text - the cached record for
PMID:30335141 is abstract-only, so no snippet can support them and the
claim would be unverifiable. They should be added if an abstract-level
source is found. Autistic features and seizures, by contrast, WERE added,
because the Basque cohort paper (PMID:31906484) quantifies both at group
level in text that is present in the cached record.
Two of Edison's citation keys resolve to distinct papers by the same Basque
group, and are cited here under their separately verified identities:
"tejada2020non-syndromicxlinked" is the dedicated NS-XLID review (Tejada &
Ibarluzea 2020, Clin Genet, PMID:31898314), and
"ibarluzea2020targetednextgenerationsequencing" is the 82-gene panel cohort
study (Ibarluzea et al. 2020, Genes, PMID:31906484). The DOI-to-PMID
converter returns no PMID for the review's DOI (10.1111/cge.13698), so it
was recovered by title search; a first pass of this curation conflated the
two keys, and the review is the source of the class definition, the
not-clear-cut boundary statement, and the 141-gene count recorded here.
Scope note. Non-syndromic X-linked intellectual disability (NS-XLID) is not one molecularly uniform disease. It is an umbrella category for numerous X-linked neurodevelopmental disorders in which intellectual disability (ID) is the only consistent shared feature. Additional neurologic, behavioral, or dysmorphic findings may occur, but do not form a reproducible syndrome. Consequently, prevalence, penetrance, natural history, biomarkers, and treatment should ideally be curated at the causal-gene/variant level rather than assigned uniformly to the umbrella term. The boundary with syndromic XLID is increasingly regarded as blurred or biologically arbitrary. (tejada2020non‐syndromicxlinked pages 1-5, neri2018x‐linkedintellectualdisability pages 3-4, tejada2020non‐syndromicxlinked pages 12-15)
The following ontology-ready summary complements the narrative report.
| Domain | Knowledge-base content | Suggested ontology terms/IDs | Evidence caveat |
|---|---|---|---|
| Disease identity | Non-syndromic X-linked intellectual disability (NS-XLID) is a genetically heterogeneous X-linked neurodevelopmental disease group in which intellectual disability is the only consistent shared feature; additional neurologic, behavioral, or dysmorphic findings may occur but are variable and gene-/family-specific. Exact disease-level knowledge is aggregated from literature/reviews and should not be overgeneralized to every gene-defined subtype. (OpenTargets Search: non-syndromic X-linked intellectual disability, tejada2020non‐syndromicxlinked pages 1-5, neri2018x‐linkedintellectualdisability pages 3-4) | MONDO:0019181; term label: non-syndromic X-linked intellectual disability | “Nonsyndromic” does not mean absence of all other findings; rather, no consistent syndromic pattern across cases. Scope overlaps with syndromic XLID for many genes. |
| Synonyms / scope | Non-specific X-linked intellectual disability; nonsyndromal X-linked intellectual disability; NS-XLID; historical: non-syndromic X-linked mental retardation. (tejada2020non‐syndromicxlinked pages 1-5, neri2018x‐linkedintellectualdisability pages 3-4) | term suggestions; verify release | Historical terminology in older papers may use outdated language. |
| Core phenotype | Intellectual disability is the defining phenotype, often mild to severe depending on gene/variant. (tejada2020non‐syndromicxlinked pages 1-5) | HP:0001249 Intellectual disability | Frequency at disease-group level cannot be meaningfully quantified because NS-XLID aggregates many disorders. |
| Core phenotype | Developmental delay / global developmental delay may precede formal ID diagnosis in childhood. (khayat2019arecurrentmissense pages 3-4, mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 2-4) | HP:0001263 Global developmental delay; HP:0011344 Severe global developmental delay | More typical in pediatric case series; adult historical families may be described primarily as ID. |
| Core phenotype | Speech/language delay or poor/absent speech is common in several gene-specific forms. (khayat2019arecurrentmissense pages 3-4, mir2023wholeexomesequencing pages 1-2, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6) | HP:0000750 Delayed speech and language development; HP:0001344 Expressive language delay | Strongly gene-dependent; not universal across all NS-XLID genes. |
| Core phenotype | Hypotonia / muscle weakness reported in subsets, including SLC9A7-related cases. (khayat2019arecurrentmissense pages 3-4) | HP:0001252 Hypotonia; HP:0001324 Muscle weakness | Variable and not specific; may reflect particular gene mechanisms. |
| Core phenotype | Seizures/epilepsy occur in some NS-XLID genes (for example IQSEC2-, GLRA2-, ATP2B3-related cases) but are inconsistent at disease-group level. (tejada2020non‐syndromicxlinked pages 12-15, mir2023wholeexomesequencing pages 1-2, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6) | HP:0001250 Seizure; HP:0002123 Generalized myoclonic seizure (term suggestion; verify release if subtyped) | Presence of seizures can shift some cases toward broader neurodevelopmental syndromes; use gene-level assertion when possible. |
| Core phenotype | Autism spectrum features / autistic traits / behavioral abnormalities / psychiatric problems may occur in subsets. (tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 19-23, mir2023wholeexomesequencing pages 1-2) | HP:0000729 Autism; HP:0000708 Behavioral abnormality | HPO choice should be tailored to reported feature (autism, aggression, hyperactivity, anxiety, etc.). |
| Anatomy | Primary organ/system affected: brain, especially forebrain/cerebral cortex and synaptic networks underlying cognition and behavior. (tejada2020non‐syndromicxlinked pages 5-8, tejada2020non‐syndromicxlinked pages 8-12, martinez2024overcominggeneticand pages 1-2) | UBERON:0000955 brain; UBERON:0000956 cerebral cortex | Disease-level anatomy is inferred from shared neurodevelopmental biology rather than uniform lesion localization. |
| Tissue / cell types | Principal affected tissue: nervous tissue; relevant cell types include excitatory neurons, inhibitory neurons, and broader cortical/hippocampal neuronal populations. (tejada2020non‐syndromicxlinked pages 8-12, martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 11-12, martinez2024overcominggeneticand pages 1-2) | CL:0000540 neuron; term suggestions: excitatory neuron, inhibitory neuron, cortical neuron, hippocampal neuron; verify release | Exact CL subtype should match gene/mechanism-specific evidence; many papers infer rather than directly prove target cell types. |
| Subcellular compartments | Recurrently implicated compartments include synapse, presynaptic vesicle, postsynaptic density, dendritic spine, nucleus/chromatin, Golgi/TGN/post-Golgi vesicles, endosome, and mitochondrion for some genes. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 5-8, tejada2020non‐syndromicxlinked pages 8-12, khayat2019arecurrentmissense pages 3-4, khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9) | GO:0045202 synapse; GO:0098793 presynapse; GO:0014069 postsynaptic density; GO:0043197 dendritic spine; GO:0005654 nucleoplasm; GO:0005794 Golgi apparatus; GO:0005802 trans-Golgi network; GO:0005768 endosome; GO:0005739 mitochondrion | Use gene-level annotation for highest confidence; not every compartment applies to every NS-XLID gene. |
| Major mechanism | Synaptic function/plasticity defects: vesicle trafficking, neurotransmitter release, postsynaptic signaling, receptor trafficking, dendritic spine regulation. Representative genes include GDI1, IL1RAPL1, SYN1, SYP, DLG3, GRIA3, IQSEC2, NLGN3, NLGN4, RAB39B, OPHN1, PAK3, TSPAN7. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 8-12) | GO:0007268 chemical synaptic transmission; GO:0016079 synaptic vesicle exocytosis; GO:0048167 regulation of synaptic plasticity | Shared pathway category is review-derived; representative genes vary in evidence strength. |
| Major mechanism | Cytoskeleton / Rho- and Arf-family GTPase signaling affecting dendrites and spines. Representative genes include IQSEC2, OPHN1, PAK3, FGD1. (tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 8-12) | GO:0032956 regulation of actin cytoskeleton organization; GO:0007015 actin filament organization | Often downstream of synaptic signaling; phenotype correlations remain incomplete. |
| Major mechanism | Transcription, chromatin, RNA processing, translation regulation. Representative genes include HCFC1, KDM5C, MECP2, MED12, PQBP1, RPS6KA3, THOC2, UPF3B, ZNF711, AFF2, ATRX, DDX3X. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 5-8, tejada2020non‐syndromicxlinked pages 19-23) | GO:0006357 regulation of transcription by RNA polymerase II; GO:0006338 chromatin remodeling; GO:0000398 mRNA splicing; GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | Many of these genes also cause syndromic XLID; classify carefully at variant/disorder level. |
| Major mechanism | Ubiquitination / proteostasis dysregulation, including neuronal proliferation/differentiation and substrate turnover. Representative genes include HUWE1, MID2, RLIM, USP9X. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 19-23) | GO:0016567 protein ubiquitination; GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process | Evidence is stronger for some genes than others; downstream neuronal effects remain incompletely resolved. |
| Major mechanism | Membrane transport / ion homeostasis / metabolism. Representative genes include SLC6A8, CLCN4, SLC16A2, SLC25A5, NDUFA1, ACSL4, ATP2B3, GLRA2. (tejada2020non‐syndromicxlinked pages 25-28, mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 4-6) | GO term suggestions: transmembrane transport, ion homeostasis, creatine transmembrane transporter activity, mitochondrial ATP transport; verify release | Some genes produce broader syndromic/metabolic phenotypes outside strict NS-XLID. |
| Major mechanism | Golgi/TGN pH regulation and glycosylation defects. Best current gene-specific example: SLC9A7 p.Leu515Phe causing altered Golgi acidification and aberrant glycosylation with abnormal transferrin N-glycosylation. (khayat2019arecurrentmissense pages 3-4, khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9) | GO:0051453 regulation of intracellular pH; GO:0006486 protein glycosylation; GO:0005794 Golgi apparatus; GO:0005802 trans-Golgi network | Mechanism currently best established for SLC9A7-related NS-XLID, not the entire disease group. |
| Causal genes / heterogeneity | Highly heterogeneous disorder group. Review-level counts reported ~56 genes implicated in NS-XLID, with many overlapping syndromic genes; 146 total XLID genes reported by 2020 review, and disease-target databases list additional associated genes. (tejada2020non‐syndromicxlinked pages 1-5, tejada2020non‐syndromicxlinked pages 23-25, OpenTargets Search: non-syndromic X-linked intellectual disability) | Gene symbols only; disease-group curation should link to gene-specific disorder records where possible | Gene lists change with reclassification; some historical genes remain uncertain/questioned. |
| Inheritance | Usually X-linked inheritance affecting males more often; female carriers may be unaffected or mildly/variably affected, influenced by X-chromosome inactivation and gene escape status. (tejada2020non‐syndromicxlinked pages 1-5, luca2020challengesinmolecular pages 1-2, martinez2024overcominggeneticand pages 1-2, chaves2023skewedxchromosomeinactivation pages 1-5) | HP:0001417 X-linked inheritance; term suggestion: X-linked recessive inheritance; verify release | Some genes act through dominant, de novo, mosaic, or dosage-sensitive mechanisms in females. |
| Diagnostics | Recommended workup typically includes clinical evaluation/family history, FMR1 testing, chromosomal microarray, and next-generation sequencing (panel, exome, or genome) with segregation analysis and variant interpretation under ACMG/AMP. (luca2020challengesinmolecular pages 1-2, ibarluzea2020targetednextgenerationsequencing pages 1-3) | NCIT term suggestions: Genetic Testing, Chromosomal Microarray Analysis, Whole Exome Sequencing, Whole Genome Sequencing; verify release | No single disease-specific laboratory biomarker exists for NS-XLID as a group. |
| Diagnostics | Exome/genome sequencing now outperforms CMA/panels for unexplained GDD/ID broadly; targeted XLID panels may still help in suggestive pedigrees. In one XLID panel study, 17 candidate variants were identified in 16/61 unrelated males after negative karyotype/FMR1 testing. (ibarluzea2020targetednextgenerationsequencing pages 1-3) | NCIT term suggestions: Whole Exome Sequencing, Next-Generation Sequencing Panel; verify release | Yield figures vary by cohort design and inclusion criteria; many statistics are for GDD/ID broadly, not NS-XLID alone. |
| Diagnostics | Functional follow-up may include RNA studies, biochemical assays, and gene-specific tests; example: urine creatine/creatinine ratio and brain MRS for SLC6A8 deficiency; transferrin glycosylation for SLC9A7-related disease. (tejada2020non‐syndromicxlinked pages 12-15, ibarluzea2020targetednextgenerationsequencing pages 1-3, khayat2019arecurrentmissense pages 2-3) | LOINC/NCIT term suggestions; CHEBI: creatine (verify ontology mapping in KB) | These are gene-specific adjuncts, not universal NS-XLID diagnostics. |
| Diagnostics in females | Extreme skewing of X-inactivation in females with idiopathic ID can enrich for pathogenic findings; in one 2023 cohort, 11/136 informative women (8%) had >=90% skewing and WES found pathogenic variants in 8/11 (73%). (chaves2023skewedxchromosomeinactivation pages 1-5) | term suggestions: skewed X-chromosome inactivation; verify release | Evidence pertains to idiopathic ID in females, not a diagnostic criterion for all NS-XLID. |
| Treatment / management | No disease-modifying therapy is established for NS-XLID as a disease group. Current care is supportive and individualized: developmental therapies, speech-language therapy, special education, behavioral/psychiatric management, and antiseizure treatment when indicated. (luca2020challengesinmolecular pages 1-2, martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10) | NCIT term suggestions: Supportive Care, Speech Therapy, Occupational Therapy, Physical Therapy, Special Education, Anticonvulsant Therapy; verify release | Management is phenotype- and gene-specific; evidence base often extrapolated from broader neurodevelopmental care. |
| Advanced therapeutics | Research directions include gene therapy, selective X-reactivation, dosage-controlled transgene strategies, and circuit/synapse-targeted interventions; these remain experimental and are mostly not NS-XLID-specific. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10, martinez2024overcominggeneticand pages 6-7, martinez2024overcominggeneticand pages 11-12) | NCIT term suggestions: Gene Therapy, CRISPR-based Gene Editing, RNA Therapy; verify release | Most therapeutic development is for specific syndromic X-linked NDDs; translation to NS-XLID is unresolved. |
| Prevention / counseling | Genetic counseling, cascade testing, carrier testing, reproductive counseling, and when a familial pathogenic variant is known, options such as prenatal diagnosis or preimplantation genetic testing. (luca2020challengesinmolecular pages 1-2, mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 4-6) | NCIT term suggestions: Genetic Counseling, Carrier Screening, Prenatal Genetic Testing, Preimplantation Genetic Testing; verify release | Prevention is primarily genetic/reproductive rather than environmental because NS-XLID is a monogenic/heterogeneous genetic disease group. |
| Epidemiology | Intellectual disability overall affects ~1% of the population; males are affected more often. XLID accounts for an estimated 5-10% of ID in males, but disease-specific prevalence for NS-XLID is not well established because it comprises many rare gene-defined disorders. (tejada2020non‐syndromicxlinked pages 1-5, luca2020challengesinmolecular pages 1-2, mir2023wholeexomesequencing pages 1-2) | No exact disease-level prevalence ID recommended | Avoid presenting a single prevalence for MONDO:0019181 as if it were a uniform entity. |
| Natural history / prognosis | Usually childhood-onset and lifelong. Course is generally chronic/stable in terms of core cognitive impairment, while associated features (seizures, behavior, speech limitations) depend on the causal gene and comorbidities. (tejada2020non‐syndromicxlinked pages 1-5, khayat2019arecurrentmissense pages 3-4, mir2023wholeexomesequencing pages 1-2) | term suggestions: childhood onset; chronic course; verify release | Prognosis cannot be generalized across all NS-XLID subtypes. |
| Models | Model systems include mouse models, human iPSCs, and cellular assays; current 2024 work emphasizes mosaic female models, reporter-based strategies, dual-eGRASP/synaptic assays, electrophysiology, imaging, and human iPSC approaches to resolve circuit heterogeneity. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10, martinez2024overcominggeneticand pages 11-12, martinez2024overcominggeneticand pages 1-2) | NCIT term suggestions: Disease Model, Induced Pluripotent Stem Cell, Mouse Model; CL:0000000 cell (generic, term suggestion for specific derived neurons); verify release | Much model literature is from broader XLID/X-linked NDDs, not exclusively strict NS-XLID. |
| Exemplary gene-specific subtype | SLC9A7-related NS-XLID: recurrent p.Leu515Phe reported in two unrelated families; associated with moderate-severe ID, speech delay, hypotonia/muscle weakness, reserved personality, clinodactyly; mechanism involves TGN/post-Golgi alkalinization and abnormal glycosylation. (khayat2019arecurrentmissense pages 3-4, khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9, khayat2019arecurrentmissense pages 45-45) | Gene: SLC9A7; GO/UBERON/HPO terms above as applicable | Useful exemplar of mechanistic depth, but not representative of all NS-XLID mechanisms. |
Table: This table provides a compact, ontology-ready summary of nonsyndromic X-linked intellectual disability for knowledge-base use. It emphasizes heterogeneous gene-dependent biology and highlights that intellectual disability is the only consistent shared feature across the disease group.
NS-XLID—also called non-specific XLID, nonsyndromal XLID, or historically X-linked nonsyndromic mental retardation—is an early-onset genetic neurodevelopmental disease group. “Non-syndromic” does not mean that every patient has isolated ID; it means no additional feature is consistently shared across the relevant family or disorder definition. The dedicated review states: “Non-Specific or Non-Syndromic Intellectual Disability (NS-XLID) [is that] where the only common feature is ID.” (tejada2020non‐syndromicxlinked pages 1-5)
The historical syndromic/non-syndromic division is unstable: different variants in one gene—and sometimes the same familial variant—can produce either label because of variant location, dosage, genetic background, X-inactivation, and other modifiers. (tejada2020non‐syndromicxlinked pages 1-5, tejada2020non‐syndromicxlinked pages 12-15)
The primary cause is a germline pathogenic or likely pathogenic X-chromosomal variant. Relevant classes include missense, nonsense, frameshift, splice-altering, repeat-expansion, exon/gene deletion or duplication, and larger structural variants. Pathogenic mechanisms include loss of function, altered dosage, impaired protein interactions, and occasional apparent gain of function. Most variants are constitutionally inherited or de novo; somatic/gonadal mosaicism is possible but not quantified for the umbrella disease.
Representative clinically supported genes include AFF2, ARX, ATRX, BRWD3, CLCN4, DLG3, FTSJ1, GDI1, HCFC1, HUWE1, IL1RAPL1, IQSEC2, KDM5C, MECP2, MED12, NLGN3, NLGN4X, OGT, OPHN1, PAK3, RAB39B, RPS6KA3, SLC6A8, SLC9A7, SYP, SYN1, TSPAN7, UPF3B, and ZNF711. Gene validity and the “non-syndromic” designation require periodic reassessment; older candidate lists contained associations later questioned by population sequencing. (OpenTargets Search: non-syndromic X-linked intellectual disability, tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 1-5)
A recent human example is the October 2023 WES study of nine affected males from four Iranian families. It identified likely pathogenic ZDHHC9 c.566T>C (p.Leu189Pro), GLRA2 c.1048C>T (p.Arg350Cys), ATP2B3 c.2541C>G (p.Asp847Glu) and previously reported pathogenic L1CAM c.925G>A (p.Glu309Lys) variants. The three novel variants were classified under ACMG/AMP criteria and segregated in X-linked pedigrees. [BMC Medical Genomics, October 2023, DOI: https://doi.org/10.1186/s12920-023-01680-y]. (mir2023wholeexomesequencing pages 1-2, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6)
No reproducible protective allele, diet, lifestyle, medication, or environmental exposure has been established for NS-XLID as a group. Favorable XCI that preferentially silences the mutant allele may reduce expression in heterozygous females, but is tissue-specific and is better considered a modifier than a dependable protective factor. The literature suggests environmental or genetic background can modify phenotype even within a family, but no validated quantitative gene–environment interaction was identified. (tejada2020non‐syndromicxlinked pages 1-5)
Defining phenotype: developmental-onset impairment of intellectual and adaptive functioning (HP:0001249 Intellectual disability), ranging from mild to profound. Developmental delay (HP:0001263) may be recognized before formal cognitive testing. Onset is congenital/developmental, generally becoming apparent in infancy or childhood; the cognitive disability is chronic and lifelong rather than episodic. (tejada2020non‐syndromicxlinked pages 1-5)
Common but non-universal, gene-dependent findings include:
These features cannot be assigned meaningful umbrella-level percentages. For example, early IQSEC2 families showed moderate-to-severe ID, while seizures, autistic traits, and psychiatric problems were inconsistent. More than 70 IQSEC2 variants had been reported by 2020, with severe truncating variants often producing a broader encephalopathy. (tejada2020non‐syndromicxlinked pages 12-15)
In the 2023 Iranian series, severe ID, developmental and speech delay were prominent; seizures, behavioral problems, muscle weakness, dysmorphism, agenesis of the corpus callosum, and colpocephaly varied by family and gene. (mir2023wholeexomesequencing pages 2-4, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6)
Quality of life: impairment chiefly affects communication, education, independent living, employment, social participation, and lifelong caregiver needs. Epilepsy, behavioral disorders, and absent speech add substantial morbidity. No NS-XLID-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life estimate was found; quantitative quality-of-life claims should therefore not be imputed from general ID cohorts.
Pathogenic variants are generally rare or absent from population databases and evaluated with ACMG/AMP criteria, segregation, phenotype consistency, XCI/escape status, and functional evidence. Healthy carrier mothers do not automatically refute pathogenicity. Conversely, rarity and in-silico prediction alone do not establish causality. RNA sequencing, biochemical assays, deep mutational scanning, and cell models can reclassify variants of uncertain significance. (luca2020challengesinmolecular pages 1-2, ibarluzea2020targetednextgenerationsequencing pages 1-3)
The variant classes and consequences are gene-specific:
Allele frequency must be documented per exact HGVS allele and genome build in gnomAD; there is no meaningful group-level allele frequency. Germline inheritance predominates. Somatic origin is not a defining feature, although mosaicism should be considered. No consistently validated modifier gene or anticipation phenomenon was found. Founder effects and carrier frequencies are variant/population-specific and not established for the umbrella entity.
Random XCI creates cellular mosaics in females; escape from XCI and tissue-specific skewing complicate penetrance and blood-to-brain inference. In a 2023 study of 194 women with idiopathic ID, 136 were informative for the androgen-receptor methylation assay; 11/136 (8%) had extreme/total skewing of at least 90%. WES diagnosed 8/11 (73%), including X-linked DDX3X, WDR45, PDHA1 and autosomal KCNB1, CTNNB1, YY1, ANKRD11 variants. Thus extreme XCI is an enrichment signal, not a standalone NS-XLID diagnostic criterion. [Molecular Neurobiology, March 2023, DOI: https://doi.org/10.1007/s12035-023-03311-0]. (chaves2023skewedxchromosomeinactivation pages 1-5)
No toxin, radiation exposure, pollutant, occupation, smoking, alcohol pattern, diet, exercise level, or infectious agent is known to cause genetically defined NS-XLID. These factors may influence general neurodevelopment, health, or seizure control, but evidence for a disease-specific causal interaction is absent. NS-XLID is neither infectious nor transmissible, and vaccination is not etiologic or preventive.
The upstream event is a pathogenic X-linked variant. The downstream chain depends on the gene, but several convergent modules emerge:
Khayat and colleagues reported the recurrent SLC9A7 c.1543C>T (p.Leu515Phe) allele in two unrelated families: four Australian males aged 65, 58, 56, and 27 years and two American males aged 36 and four years. Clinical findings included moderate-to-severe ID, speech delay, hypotonia/muscle weakness, reserved personality, variable reflexes, and bilateral clinodactyly; carrier females were clinically unaffected. [Human Molecular Genetics, October 2019; PMID 30335141; DOI: https://doi.org/10.1093/hmg/ddy371]. (khayat2019arecurrentmissense pages 3-4, khayat2019arecurrentmissense pages 45-45)
SLC9A7/NHE7 normally localizes predominantly to the trans-Golgi network (TGN) and post-Golgi vesicles. The mutant retained localization and had a nonsignificantly shorter half-life—2.2 ± 0.43 versus 2.92 ± 1.52 hours—but alkalinized TGN/post-Golgi compartments, impaired N-linked oligosaccharide maturation, and produced abnormal serum-transferrin N-glycosylation. The causal chain is therefore: missense variant → dysregulated organellar proton/cation exchange → Golgi alkalinization → abnormal cargo glycosylation → altered neuronal protein processing → neurodevelopmental impairment. Evidence is human genetic plus serum biochemical and transfected-cell functional evidence, not yet proof of every downstream brain step. (khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9)
Relevant cells are principally neurons—especially cortical and hippocampal excitatory and inhibitory populations—and their synapses; glia may participate in selected disorders. Suggested terms include CL:0000540 neuron, plus release-verified cortical, glutamatergic, GABAergic, and hippocampal neuronal subclasses. The primary organ is the brain (UBERON:0000955), particularly cerebral cortex (UBERON:0000956) and distributed cognitive circuits. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 11-12, martinez2024overcominggeneticand pages 1-2)
There is no common autoimmune, immunodeficiency, inflammatory, ischemic, fibrotic, necrotic, or oxidative-tissue-injury mechanism for NS-XLID as a whole. Likewise, no validated umbrella-level transcriptomic, proteomic, metabolomic, or lipidomic diagnostic signature exists. Gene-specific data include transferrin glycosylation in SLC9A7 and creatine abnormalities in SLC6A8. Single-cell, spatial-transcriptomic, and integrated multi-omic findings remain research-stage and are not sufficiently uniform for disease-group annotation.
Secondary organ involvement is not intrinsic to strict NS-XLID. Consistent extracerebral abnormalities should prompt reconsideration of a gene-specific syndromic diagnosis.
Onset is developmental, usually recognized through delayed milestones, language delay, learning difficulty, or adaptive impairment in infancy or childhood. ID is chronic and lifelong. The core cognitive deficit is usually relatively stable rather than relapsing-remitting, although developmental gains occur and comorbid epilepsy or behavior may fluctuate. There is no accepted staging system, remission pattern, or end stage for the umbrella disease.
Early childhood is the key period for diagnostic testing and developmental intervention because neuroplasticity and acquisition of communication/adaptive skills are greatest. Evidence does not support spontaneous cure. Gene-specific disorders may be progressive or epileptic-encephalopathic and should not be generalized to strict NS-XLID.
Inheritance is usually X-linked: hemizygous males are more frequently and often more severely affected, while heterozygous females range from unaffected to severely affected depending on XCI, escape, dosage, and variant mechanism. Some genes behave as X-linked dominant disorders with frequent de novo female cases rather than conventional recessive traits. (luca2020challengesinmolecular pages 1-2, martinez2024overcominggeneticand pages 1-2, chaves2023skewedxchromosomeinactivation pages 1-5)
ID overall is reported around 1%, with male prevalence approximately 30% higher than female prevalence in one meta-analytic summary. XLID mutations account for an estimated 5–10% of male ID, but strict NS-XLID prevalence, incidence, carrier frequency, geographic distribution, and male:female ratio are unavailable. (tejada2020non‐syndromicxlinked pages 1-5, luca2020challengesinmolecular pages 1-2)
Penetrance and expressivity are gene- and sex-dependent. Germline mosaicism is relevant for counseling after an apparently de novo result, but no umbrella recurrence percentage is available. Genetic anticipation is not characteristic, except that AFF2/FMR2- and FMR1-related repeat biology must be handled under their specific disease definitions. Consanguinity is not a primary risk factor for X-linked disease, although it can clarify or complicate pedigrees. Founder alleles and population differences must be assessed variant by variant; the 2023 Iranian family study illustrates the importance of studying underrepresented ancestries but does not establish a general regional excess. (mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 4-6)
In a panel study of 61 unrelated males with suggestive NS-XLID after normal karyotype and FMR1 testing, sequencing 82 XLID genes found 17 candidate variants in 16 patients. The authors cited approximately 25% diagnostic yields for panel/X-exome strategies and stressed segregation, RNA, and biochemical follow-up. [Genes, January 2020, DOI: https://doi.org/10.3390/genes11010051]. (ibarluzea2020targetednextgenerationsequencing pages 1-3)
Gene-specific adjuncts include elevated urine creatine/creatinine and reduced brain creatine by proton MRS for SLC6A8 deficiency, and serum-transferrin N-glycosylation for SLC9A7. These are not universal NS-XLID biomarkers. (tejada2020non‐syndromicxlinked pages 12-15, khayat2019arecurrentmissense pages 2-3)
Differentials include Fragile X syndrome, syndromic XLID, autosomal dominant/recessive ID, chromosomal CNVs, mitochondrial disease, cerebral palsy, fetal alcohol exposure, congenital infection, endocrine/metabolic disorders, autism without ID, and acquired brain injury. There are no universal NS-XLID clinical criteria beyond developmental ID plus a confirmed causal X-linked diagnosis and absence of a consistent defining syndrome.
No population newborn screen exists. Appropriate screening comprises cascade testing after a familial diagnosis, targeted carrier testing, and variant-specific prenatal/preimplantation testing. Broad carrier screening may not capture all genes/variant classes.
No NS-XLID-specific survival curves, mortality rates, or life-expectancy estimates were identified. Isolated cognitive disability is not inherently life-limiting, but prognosis varies with epilepsy, aspiration, mobility, congenital anomalies, or gene-specific systemic disease. Functional morbidity is lifelong and may include dependence in communication, education, employment, finances, and daily living.
Recovery to typical cognition is not expected, although developmental, educational, and communication gains can be substantial. Prognostic factors are causal gene/variant, severity of early delay, epilepsy burden, speech acquisition, motor ability, behavior, and access to intervention. No validated molecular prognostic biomarker applies across NS-XLID.
There is no FDA/EMA-approved pharmacotherapy, surgery, cell therapy, immunotherapy, RNA therapy, or gene therapy for NS-XLID as an umbrella disease. Current real-world management is multidisciplinary:
Suggested NCIT intervention concepts, with current-release verification, are Supportive Care, Speech Therapy, Occupational Therapy, Physical Therapy, Behavioral Therapy, Genetic Counseling, Anticonvulsant Therapy, Whole Exome Sequencing, and Gene Therapy.
A ClinicalTrials.gov search did not identify a disease-modifying interventional trial for strict NS-XLID. Relevant research infrastructure includes NCT02854956, a broad XLID clinical phenotyping/neural-network study, and NCT06500260, an observational CNKSR2 natural-history study. Trials for Fragile X, Rett, or CDKL5-related disease should not be represented as treatments for NS-XLID.
Experimental directions include AAV gene replacement, dosage-controlled transgenes, RNA destabilization/microRNA regulatory elements, and selective reactivation of the healthy inactive X chromosome. Experts emphasize that mosaic females create a central safety problem: indiscriminate expression may rescue mutant cells while overdosing cells already expressing the normal allele. CRISPR/pharmacologic X-reactivation currently lacks adequate cellular specificity. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10, martinez2024overcominggeneticand pages 6-7)
Primary prevention through lifestyle modification, vaccination, or environmental avoidance is not applicable to a monogenic disease group. Actionable prevention is reproductive and family-based:
Secondary/tertiary prevention consists of early diagnosis, timely therapy, seizure recognition, safety planning, and prevention of avoidable complications. There is no prophylactic drug or immunization specific to NS-XLID. (luca2020challengesinmolecular pages 1-2, mir2023wholeexomesequencing pages 1-2)
No naturally occurring veterinary disease corresponding to the aggregate human NS-XLID category was identified. The condition is not infectious, zoonotic, or cross-species transmissible. Orthologous genes are widely conserved in mammals and other vertebrates, but NCBI Gene/Taxonomy identifiers must be attached gene by gene rather than to the umbrella disease. Relevant experimental species include Homo sapiens (NCBI Taxon 9606) and Mus musculus (10090); zebrafish, Drosophila, and cultured mammalian cells are also plausible gene-specific systems. No VBO breed association is applicable at group level.
Model choice is gene-specific. Available approaches include knockout, knock-in, conditional, reporter, and mosaic mice; transfected mammalian cells; patient-derived fibroblasts; human iPSCs and differentiated neurons; and, for selected genes, zebrafish or invertebrate models.
The 2024 expert review highlights a major limitation: conventional hemizygous knockout mice do not reproduce the cellular mosaicism of heterozygous human females. Proposed F1 crosses combine X-linked reporters with mutant alleles so wild-type and mutant cells can be distinguished while retaining random XCI. dual-eGRASP, split-biotin-ligase systems, electrophysiology, calcium/voltage imaging, optogenetics, and chemogenetics can then resolve cell-type-specific synaptic and circuit defects. [Journal of Neurodevelopmental Disorders, February 2024, DOI: https://doi.org/10.1186/s11689-024-09517-0]. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10)
Evidence from broader X-linked neurodevelopmental models includes abnormal allele-specific neuronal clustering and circuit development in mosaic PCDH19 models, altered callosal/hippocampal NMDA-receptor circuitry in CDKL5 models, patient-derived CDKL5 iPSCs, and experimental rescue of dendritic-spine instability with IGF-1. These are mechanistically informative but are not direct treatment evidence for strict NS-XLID. (martinez2024overcominggeneticand pages 6-7, martinez2024overcominggeneticand pages 11-12)
References
(tejada2020non‐syndromicxlinked pages 1-5): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(neri2018x‐linkedintellectualdisability pages 3-4): Giovanni Neri, Charles E. Schwartz, Herbert A. Lubs, and Roger E. Stevenson. X‐linked intellectual disability update 2017. American Journal of Medical Genetics Part A, 176:1375-1388, Jun 2018. URL: https://doi.org/10.1002/ajmg.a.38710, doi:10.1002/ajmg.a.38710. This article has 154 citations.
(tejada2020non‐syndromicxlinked pages 12-15): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(OpenTargets Search: non-syndromic X-linked intellectual disability): Open Targets Query (non-syndromic X-linked intellectual disability, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(tejada2020non‐syndromicxlinked pages 23-25): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(luca2020challengesinmolecular pages 1-2): Chiara De Luca, Valérie Race, Liesbeth Keldermans, Marijke Bauters, and Hilde Van Esch. Challenges in molecular diagnosis of x-linked intellectual disability. British medical bulletin, Feb 2020. URL: https://doi.org/10.1093/bmb/ldz039, doi:10.1093/bmb/ldz039. This article has 36 citations and is from a peer-reviewed journal.
(mir2023wholeexomesequencing pages 1-2): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.
(ibarluzea2020targetednextgenerationsequencing pages 1-3): Nekane Ibarluzea, Ana Belén de la Hoz, Olatz Villate, Isabel Llano, Intzane Ocio, Itxaso Martí, Miriam Guitart, Elisabeth Gabau, Fernando Andrade, Blanca Gener, and María-Isabel Tejada. Targeted next-generation sequencing in patients with suggestive x-linked intellectual disability. Genes, 11:51, Jan 2020. URL: https://doi.org/10.3390/genes11010051, doi:10.3390/genes11010051. This article has 34 citations.
(martinez2024overcominggeneticand pages 7-8): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.
(martinez2024overcominggeneticand pages 8-10): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.
(martinez2024overcominggeneticand pages 6-7): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.
(khayat2019arecurrentmissense pages 3-4): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.
(mir2023wholeexomesequencing pages 2-4): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.
(mir2023fourfamilieswith pages 9-11): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad-Amin Tabatabaiefar. Four families with x-linked intellectual disability affected males: novel deleterious variants and clinical features with the review of literature. Unknown journal, Apr 2023. URL: https://doi.org/10.21203/rs.3.rs-2833503/v1, doi:10.21203/rs.3.rs-2833503/v1.
(mir2023wholeexomesequencing pages 4-6): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.
(tejada2020non‐syndromicxlinked pages 19-23): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(tejada2020non‐syndromicxlinked pages 5-8): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(tejada2020non‐syndromicxlinked pages 8-12): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(martinez2024overcominggeneticand pages 1-2): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.
(martinez2024overcominggeneticand pages 11-12): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.
(khayat2019arecurrentmissense pages 2-3): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.
(khayat2019arecurrentmissense pages 8-9): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.
(tejada2020non‐syndromicxlinked pages 25-28): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.
(chaves2023skewedxchromosomeinactivation pages 1-5): Luiza D. Chaves, Laura M. L. Carvalho, Giovanna C. Tolezano, Sara F. Pires, Silvia S. Costa, Marília O. de Scliar, Liane de R. Giuliani, Debora R. Bertola, Cíntia B. Santos-Rebouças, Go Hun Seo, Paulo A. Otto, Carla Rosenberg, Angela M. Vianna-Morgante, and Ana C. V. Krepischi. Skewed x-chromosome inactivation in women with idiopathic intellectual disability is indicative of pathogenic variants. Molecular Neurobiology, 60:3758-3769, Mar 2023. URL: https://doi.org/10.1007/s12035-023-03311-0, doi:10.1007/s12035-023-03311-0. This article has 11 citations and is from a peer-reviewed journal.
(khayat2019arecurrentmissense pages 45-45): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.
(neri2018x‐linkedintellectualdisability pages 1-3): Giovanni Neri, Charles E. Schwartz, Herbert A. Lubs, and Roger E. Stevenson. X‐linked intellectual disability update 2017. American Journal of Medical Genetics Part A, 176:1375-1388, Jun 2018. URL: https://doi.org/10.1002/ajmg.a.38710, doi:10.1002/ajmg.a.38710. This article has 154 citations.